abdullah's picture
Add files using upload-large-folder tool
8de7e09 verified
raw
history blame
52.5 kB
1
00:00:01,260 --> 00:00:05,520
ุจุณู… ุงู„ู„ู‡ ุงู„ุฑุญู…ู† ุงู„ุฑุญูŠู… ู†ุชุญุฏุซ ุงู„ูŠูˆู… ุนู† ุงู„
2
00:00:05,520 --> 00:00:10,060
immunodeficiency syndrome ูˆ ุงู„ immunodeficiency
3
00:00:10,060 --> 00:00:17,340
syndrome ูˆู‡ูŠ ู…ู‚ุณู…ุฉ ู…ุฑุฉ
4
00:00:17,340 --> 00:00:21,500
ุฃุฎุฑู‰ ุจุณู… ุงู„ู„ู‡ ุงู„ุฑุญู…ู† ุงู„ุฑุญูŠู… ู†ุชุญุฏุซ ุงู„ูŠูˆู… ุนู† ุงู„
5
00:00:21,500 --> 00:00:25,780
immunodeficiency syndrome these are divided into
6
00:00:25,780 --> 00:00:30,720
two major categories ู‚ุณู…ู†ุงู‡ู… ุฅู„ู‰ ู‚ุณู…ูŠู† ุฃุณุงุณูŠูŠู†
7
00:00:30,720 --> 00:00:33,260
ููŠู‡ primary immune deficiency ูˆ ููŠู‡ secondary
8
00:00:33,260 --> 00:00:38,740
immune deficiency ุทุจุนุง ููŠ ูƒู„ุชุง ุงู„ุญุงู„ุชูŠู† ู‡ู†ุงูƒ ุญุงู„ุงุช
9
00:00:38,740 --> 00:00:43,460
ู…ุฑุถูŠุฉ ู…ุชุจุงูŠู†ุฉ ุณู†ุชุทุฑู‚ ู„ุฃู…ุซู„ุฉ ูƒุซูŠุฑุฉ ููŠ ูƒู„ ู†ูˆุน ู…ู† ู‡ุฐู‡
10
00:00:43,460 --> 00:00:52,620
ุงู„ุฃู†ูˆุงุน the categories
11
00:00:52,620 --> 00:00:58,050
of primary immune response ุงูˆ deficiency ุทูŠุจ ู†ุญู†
12
00:00:58,050 --> 00:01:01,030
ุณู†ุชุทุฑู‚ ููŠ ุงู„ุจุฏุงูŠุฉ ู„ู„ primary immune deficiency ุซู…
13
00:01:01,030 --> 00:01:04,310
ุณู†ุชู‚ู„ ุงู„ู‰ ุงู„ secondary immune deficiency ุฌุงู†ุง ููŠ
14
00:01:04,310 --> 00:01:08,130
ุงู„ primary immune deficiency ู‡ูŠ ุนุจุงุฑุฉ ุนู† ุนูˆุงู…ู„
15
00:01:08,130 --> 00:01:12,970
ุฃุณุงุณูŠุฉ ู„ู„ immune response ุฃูˆ ุจุงู„ุชุงู„ูŠ ู†ุชุญุฏุซ ุนู† T
16
00:01:12,970 --> 00:01:17,410
cell ูŠุนู†ูŠ cell mediated immunity ูˆ ู†ุชุญุฏุซ ุนู† B
17
00:01:17,410 --> 00:01:21,070
cell ูŠุนู†ูŠ antibody mediated immunity ู†ุชุญุฏุซ ุนู†
18
00:01:21,070 --> 00:01:28,590
both B and T cell immunity ุซู… Non-specific immunity
19
00:01:28,590 --> 00:01:36,490
ู…ุชู…ุซู„ุฉ ุจุงู„ูุงุฌูˆุณูŠุชูƒ ุณูŠู„ and or ุงู†ูƒูŠ ุณูŠู„ ุซู… ุงู„
20
00:01:36,490 --> 00:01:42,490
complement activation ุฃูŠุถุง ูˆุทุจุนุง ูƒู„ ู‡ุฐู‡ ุงู„ุนูˆุงู…ู„
21
00:01:42,490 --> 00:01:48,190
ู…ุดุชุฑูƒุฉ ุจุชู…ุซู„ ุงู„ category of primary immune
22
00:01:48,190 --> 00:01:52,070
response ุณู†ุชุทุฑู‚ ุงู„ู‰ ูƒู„ ุนุงู…ู„ ู…ู† ู‡ุฐู‡ ุงู„ุนูˆุงู…ู„ ูˆ ู†ุฃุฎุฐ
23
00:01:52,070 --> 00:01:57,100
ุฃู…ุซู„ุฉ ุจุฏุงูŠุฉ ู…ุง ูƒุชุด ุจุชุดูƒ ููŠ ูˆุฌูˆุฏ immunodeficiency
24
00:01:57,100 --> 00:02:05,380
ู‚ุงู„ูˆุง ููŠู‡ ุนุดุฑ ู…ุญุงุฐูŠุฑ ุฃุณุงุณูŠุฉ ู…ุธุงู‡ุฑ ุฃุณุงุณูŠุฉ for
25
00:02:05,380 --> 00:02:10,740
immunodeficiency disease ู†ู…ุฑุง ูˆุงุญุฏ six or more
26
00:02:10,740 --> 00:02:14,320
infections per year ูŠุนู†ูŠ ุฃูƒุซุฑ ู…ู† ุณุช ู…ุฑุงุช ุชุญุตู„ ููŠู‡ุง
27
00:02:14,320 --> 00:02:17,820
infection ููŠ ุงู„ุณู†ุฉ ู†ู…ุฑุง ุงุชู†ูŠู† two or more severe
28
00:02:17,820 --> 00:02:22,360
sinusitis per year ู†ู…ุฑุง ุชู„ุงุชุฉ antibiotic treatment
29
00:02:22,360 --> 00:02:27,780
lasting for two months or even longer ุจุฏูˆู† ุฃูŠ
30
00:02:27,780 --> 00:02:33,900
visible effect ู†ู…ุฑุง ุฃุฑุจุนุฉ two or more pneumonia
31
00:02:33,900 --> 00:02:39,800
per year ู†ู…ุฑุง ุฎู…ุณุฉ retardation of growth and
32
00:02:39,800 --> 00:02:44,920
development of child ู†ู…ุฑุง ุณุชุฉ recurrent deep skin
33
00:02:44,920 --> 00:02:50,610
or organ abscesses ู†ู…ุฑุฉ ุณุจุนุฉ ู…ูŠูƒูˆุณูŠุณ ู…ุณุชู…ุฑ ููŠ ุงู„ุนู…ู„
34
00:02:50,610 --> 00:02:52,630
ุนู…ู„ ุนู…ู„ ุนู…ู„ ุนู…ู„ ุนู…ู„ ุนู…ู„ ุนู…ู„ ุนู…ู„ ุนู…ู„ ุนู…ู„ ุนู…ู„
35
00:02:52,630 --> 00:02:56,110
ุนู…ู„ ุนู…ู„ ุนู…ู„ ุนู…ู„ ุนู…ู„ ุนู…ู„ ุนู…ู„ ุนู…ู„ ุนู…ู„ ุนู…ู„ ุนู…ู„
36
00:02:56,110 --> 00:02:57,110
ุนู…ู„ ุนู…ู„ ุนู…ู„ ุนู…ู„ ุนู…ู„ ุนู…ู„ ุนู…ู„ ุนู…ู„ ุนู…ู„ ุนู…ู„ ุนู…ู„
37
00:02:57,110 --> 00:02:57,130
ุนู…ู„ ุนู…ู„ ุนู…ู„ ุนู…ู„ ุนู…ู„ ุนู…ู„ ุนู…ู„ ุนู…ู„ ุนู…ู„ ุนู…ู„ ุนู…ู„
38
00:02:57,130 --> 00:02:57,530
ุนู…ู„ ุนู…ู„ ุนู…ู„ ุนู…ู„ ุนู…ู„ ุนู…ู„ ุนู…ู„ ุนู…ู„ ุนู…ู„ ุนู…ู„ ุนู…ู„
39
00:02:57,530 --> 00:02:57,610
ุนู…ู„ ุนู…ู„ ุนู…ู„ ุนู…ู„ ุนู…ู„ ุนู…ู„ ุนู…ู„ ุนู…ู„ ุนู…ู„ ุนู…ู„ ุนู…ู„
40
00:02:57,610 --> 00:03:01,590
ุนู…ู„ ุนู…ู„ ุนู…ู„ ุนู…ู„ ุนู…ู„ ุนู…ู„ ุนู…ู„ ุนู…ู„ ุนู…ู„ ุนู…ู„ ุนู…ู„
41
00:03:01,590 --> 00:03:10,320
ุนู…ู„ ุนู…ู„ ุนู…ู„ ุนู…ู„ ุนู…ู„ ุนู…ู„ ู†ู…ุฑุง ุชุณุนุฉ two or more severe
42
00:03:10,320 --> 00:03:14,740
infection ุฒูŠ encephalitis, osteitis, dermatitis,
43
00:03:14,860 --> 00:03:19,440
myositis and sepsis ู†ู…ุฑุง ุนุดุฑุฉ family history
44
00:03:19,440 --> 00:03:27,680
indicating primary immune deficiency ุทุจุนุง ููŠ ุนู†ุฏู†ุง
45
00:03:27,680 --> 00:03:32,980
ุฌุฏูˆู„ ุฅู† ุดุงุก ุงู„ู„ู‡ ุณู†ุชุทุฑู‚ ุฅู„ูŠู‡ ูˆ ูŠุจูŠู† ู„ู†ุง
46
00:03:32,980 --> 00:03:37,090
different types of infection ุนู„ู‰ ุณุจูŠู„ ุงู„ู…ุซุงู„ ูƒุงู†ุช
47
00:03:37,090 --> 00:03:41,670
ุจูƒุชูŠุฑูŠุง ุงู„ู‚ุทุงุนุชุณ ู…ูŠุฏูŠุง ูˆ ุจูƒุชูŠุฑูŠุง ุงู„ู†ูˆู…ูˆู†ูŠุง ุบุงู„ุจุง
48
00:03:41,670 --> 00:03:44,470
ู†ุฑุงู‡ุง ููŠ ุงู„ู†ุงุณ ุงู„ู„ูŠ ุนู†ุฏู‡ู… B cell and antibody
49
00:03:44,470 --> 00:03:49,970
deficiency ูˆ ู‡ูƒุฐุง ุฌุฏูˆู„ ู…ุตู†ู ุงู†ู‡ุง ุจุงู„ุฐุงุช ุฃู…ุฑุงุถ
50
00:03:49,970 --> 00:03:56,590
ูƒุซูŠุฑุฉ ูˆ ุบูŠุงุจ ูƒู„ ูˆุงุญุฏ ุดูˆ ุจูŠุนู…ู„ ูุฃูˆู„ ูˆุงุญุฏ B cell ุฃูˆ
51
00:03:56,590 --> 00:04:01,420
B lymphocyte deficiency which means deficiency in
52
00:04:01,420 --> 00:04:05,600
antibody-mediated immunity ููˆู‚ ุจูŠุตูŠุฑ ููŠู‡ recurrent
53
00:04:05,600 --> 00:04:08,260
bacterial infection ูˆ ุชุนุชุจุฑ recurrent infection
54
00:04:08,260 --> 00:04:11,960
ูˆ ู‡ูƒุฐุง T cell deficiency ูŠุนู†ูŠ cell-mediated
55
00:04:11,960 --> 00:04:15,920
immunity deficiency ูŠุฒูŠุฏ ุงู„ susceptibility to the
56
00:04:15,920 --> 00:04:19,460
viral fungal protozoa ูˆ ุงู„ infection ูˆู‡ูŠ ู…ุฌู…ูˆุนุฉ
57
00:04:19,460 --> 00:04:24,820
ูƒุจูŠุฑุฉ ู…ู† ุนูŠุด ู…ู† ุงู„ุญุงู„ุงุช ุงู„ู…ุฑุถูŠุฉ ูƒู„ ูˆุงุญุฏ ู„ู‡ ุนูŠุด ู„ู‡
58
00:04:24,820 --> 00:04:27,080
ุงู„ associated disease
59
00:04:29,920 --> 00:04:32,720
ุชุฎูŠู„ ุงู†ู†ุง ู†ุจุฏุฃ ู†ุญูƒูŠ ุนู†ู‡ุง ุงู„ primary
60
00:04:32,720 --> 00:04:38,440
immunodeficiency syndromes ูŠุนู†ูŠ ุจุงุณุชุซู†ุงุก ุงู„ IGA
61
00:04:38,440 --> 00:04:42,260
deficiency ุงู„ frequency of immunodeficiency is
62
00:04:42,260 --> 00:04:48,460
very low ุญุฏุฏูˆู‡ุง ูˆุงุญุฏ ููŠ ูƒู„ ุนุดุฑ ุชู„ุงู ุฎู…ุณูŠู† ุจุงู„ู…ุฆุฉ
63
00:04:48,460 --> 00:04:53,520
ู…ู†ู‡ู… associated with antibody deficiency ุนุดุฑูŠู†
64
00:04:53,520 --> 00:04:59,350
ุจุงู„ู…ุฆุฉ ู…ู†ู‡ู… associated with combined deficiency ุจู…ุนู†ู‰ ุงู†ู‡
65
00:04:59,350 --> 00:05:03,850
ููŠู‡ antibody ูˆ cell-mediated immunity 18% for
66
00:05:03,850 --> 00:05:07,590
phagocystic disorders 10% for cell-mediated
67
00:05:07,590 --> 00:05:15,810
immunity alone ุงู„ููƒุฑุฉ ุงู„ู‚ุงุฏู…ุฉ P1.1 ูŠุจูŠู† ุงู† ูƒู„ ู…ุง
68
00:05:15,810 --> 00:05:20,830
ูƒุงู† ุงู„ defect earlier ูƒู„ ู…ุง ูƒุงู† ุงู„ genetic defect
69
00:05:20,830 --> 00:05:24,830
ุฃูˆ ุงู„ block ุญุฏุซ
70
00:05:24,830 --> 00:05:30,330
ููŠ ุฏุฑุงุนูŠ ุงู„ู„ู‰ ู‡ูˆ ุงู„ุฌู‡ุงุฒ ุงู„ู…ู†ุงุนูŠ ูƒู„ ู…ุง ูƒุงู† earlier
71
00:05:30,330 --> 00:05:38,850
ูƒู„ ู…ุง ูƒุงู† ุงู„ effect more severe and diseaseable
72
00:05:38,850 --> 00:05:45,160
ุดูˆููˆุง ุงู„ูุฌุฑ ุทุจุนุง ู‡ุฐุง figure ุงู„ู„ูŠ ุฃู†ุชู… ุดุงูŠููŠู† ูŠุจูŠู†
73
00:05:45,160 --> 00:05:51,460
ุงู† ุงู„ hemopoietic maturation steps for both T and
74
00:05:51,460 --> 00:05:58,400
B lymphocytes ู I ุจูŠ ุนู„ู‰ ุณุจูŠู„ ุงู„ู…ุซุงู„ ุจุฏุงูŠุชู‡ุง
75
00:05:58,400 --> 00:06:04,050
lymphoid stem cell ุซู… pre-cell ุซู… immature cell ุซู…
76
00:06:04,050 --> 00:06:07,970
ุงู„ mature ุจูŠู‡ lymphocytes ุงู„ู„ูŠ ุทุจุนุง ุจุนุฏู‡ุง ุจุชุฏูŠู†ุง
77
00:06:07,970 --> 00:06:12,430
different types of antibody once ุงู„ู„ูŠ ู‡ูˆ
78
00:06:12,430 --> 00:06:18,090
maturation occur to plasma cell ููŠ ูƒู„ ู…ุฑุญู„ุฉ ู…ู†
79
00:06:18,090 --> 00:06:23,570
ุงู„ู…ุฑุงุญู„ ู…ู…ูƒู† ูŠุญุตู„ ููŠู‡ defect ูˆ ูƒู„ ู…ุฑุญู„ุฉ ู…ู† ุงู„ู…ุฑุงุญู„
80
00:06:23,570 --> 00:06:27,950
associated with certain disease ูˆ ูƒู„ ู…ุง ูƒุงู†ุช
81
00:06:27,950 --> 00:06:36,070
ุงู„ู…ุฑุญู„ุฉ ุฃูˆ ุงู„ุฎู„ู„ ุจุฏุฑูŠ ูƒู„ ู…ุง ูƒุงู†ุด ูƒู„ ุงู„ู…ุฑุงุญู„ ุงู„ุชูŠ
82
00:06:36,070 --> 00:06:41,710
ุชู„ูŠ ุงู„ุฎู„ู„ ุจุฏู‡ุง ุชุชุนุทู„ ูˆุจุงู„ุชุงู„ูŠ ูƒู„ ู…ุง ูƒุงู† ุงู„ disease
83
00:06:41,710 --> 00:06:45,290
more severe ู†ูุณ ุงู„ุญูƒุงูŠุฉ ุจุงู„ู†ุณุจุฉ ู„ู„ thymus ุฃูˆ ุงู„
84
00:06:45,290 --> 00:06:49,750
telephocytes ู‡ูŠ ุจุชูŠุฌูŠ ุนู„ู‰ ุงู„ thymus
85
00:06:52,580 --> 00:06:59,000
ุจุนุฏ ุฐู„ูƒ ุชุธู‡ุฑ ูƒู€ mature CD4 ุฃูˆ CD8 T lymphocytes
86
00:06:59,000 --> 00:07:05,280
ูˆุทุจุนุง ุชุดุชุบู„ ูƒ immune
87
00:07:05,280 --> 00:07:10,600
cell ุงู„ู…ู‡ู… ุงู†ุชุจู‡ูˆุง ุฅู„ู‰ ุงู„ุฃุฑู‚ุงู… ุงู„ู…ูˆุฌูˆุฏุฉ ูุดูˆููˆุง
88
00:07:10,600 --> 00:07:15,600
ู‚ุณู…ูˆุง ุงู„ู…ุฑุงุญู„ ู‡ุฐู‡ ุฅู„ู‰ ุฃุฑู‚ุงู… ู…ุฎุชู„ูุฉ ูˆ ูƒู„ ู…ุฑุญู„ุฉ
89
00:07:15,600 --> 00:07:19,120
associated ุฒูŠ ู…ุง ู‚ู„ุชู„ูƒู… or combined with a certain
90
00:07:19,120 --> 00:07:24,000
disease ูุฑู‚ 1 ุนู„ู‰ ุณุจูŠู„ ุงู„ู…ุซุงู„ ู‡ูŠ ูŠุนู†ูŠ ููŠ ุจุฏุฑูŠ ุฎุงู„ุต
91
00:07:24,000 --> 00:07:27,120
ุงู„ุฎู„ู„ ุจูŠุตูŠุฑ ููŠ severe compound immunodeficiency
92
00:07:27,120 --> 00:07:32,200
syndrome ุฑู‚ู… ุงุชู†ูŠู† ุจุฑุถู‡ ุจุฏุฑูŠ ุฃุฏุงุฉ ุจูŠุตูŠุฑ ููŠ
93
00:07:32,200 --> 00:07:36,000
congenital thymic aplasia ูˆุจุฑุถู‡ ู‡ุฐุง ุนุจุงุฑุฉ ุนู† ุฏูŠ
94
00:07:36,000 --> 00:07:40,020
ุฌุงุฑุณ ุณู†ุฏุฑูˆู… ูŠุนู†ูŠ ู…ุงููŠุด T lymphocytes ุจุชุชุตู†ุน ุฃุชูˆู„
95
00:07:40,020 --> 00:07:47,480
ุฑู‚ู… ุชู„ุงุชุฉ ุฃุฏุงุฉ ุจูŠุตูŠุฑ ููŠ skid ุงูŠุถุง ุฑู‚ู… ุงุฑุจุน ููŠ ุงู„ B
96
00:07:47,480 --> 00:07:51,610
cell ุฃุฏุงุฉ ู‚ุงู„ูˆุง ุจูŠุตูŠุฑ ููŠ X-Linked E Gamma Global
97
00:07:51,610 --> 00:07:58,530
Anemia ู…ุงููŠุด ูˆู„ุง Antibody ุจูŠุชูƒูˆู† ุฑู‚ู… ุฎู…ุณุฉ ู…ุงุดูŠ ู‡ุฐุง
98
00:07:58,530 --> 00:08:03,570
ู‡ูˆ ุฃู†ุง ุฑู‚ู… ุฎู…ุณุฉ ุจูŠุตูŠุฑ common variable immune
99
00:08:03,570 --> 00:08:09,670
deficiency disease ูˆ ู‡ูƒุฐุง ูƒู„ ุงู„ุญุงู„ุงุช ุงู„ู„ูŠ ู‡ูˆ ูƒู„
100
00:08:09,670 --> 00:08:16,440
ุงู„ู…ุฑุงุญู„ associated with certain disease ู†ุจุฏุฃ ุจู€
101
00:08:16,440 --> 00:08:22,600
Severe Combined Immunodeficiency Diseases ูˆู‡ูŠ
102
00:08:22,600 --> 00:08:26,640
ุนุจุงุฑุฉ ุนู† ู‡ูŠุชุฑูˆุฌูŠู†ุณ ุฌุฑูˆุจ of disease associated or
103
00:08:26,640 --> 00:08:29,700
in which cell-mediated immunity and antibody ู„ุฃู†ู‡
104
00:08:29,700 --> 00:08:35,060
combined production are defected ุงู„ุงุซู†ูŠู† ู…ุนุทู„ูŠู†
105
00:08:35,060 --> 00:08:38,960
both humoral and cell-mediated immunity are
106
00:08:38,960 --> 00:08:44,940
defected ููŠ ุงู„ุฒู…ู† ู‡ุชุณู…ูˆู‡ุง ุฃูˆ Swiss-type Aiga
107
00:08:44,940 --> 00:08:49,820
Microbial Anemia ูˆ ุงู„ู†ุงุณ ู‡ุฏูˆู„ ุนุงุฏุฉ susceptible to
108
00:08:49,820 --> 00:08:54,060
virtually every type of microbial infection, viral
109
00:08:54,060 --> 00:08:59,040
infection, bacterial infection, fungal, protozoal
110
00:08:59,040 --> 00:09:04,380
and so on ุฃุดู‡ุฑ ุงู„ุญุงุฌุงุช ุงู„ู„ูŠ ู…ู„ุญูˆุธุฉ ููŠ ู‡ุฐุง ุงู„ู†ูˆุน ู…ู†
111
00:09:04,380 --> 00:09:08,380
ุงู„ุฃู…ุฑุงุถ ู‡ูˆ Infection of Cytomegalovirus,
112
00:09:08,980 --> 00:09:16,220
Pneumocystitiscarny eye and candida ุทุจุนุง ุงู„ู†ุงุณ ุฏูˆู„
113
00:09:16,220 --> 00:09:23,260
ู…ู…ู†ูˆุน ูŠุงุฎุฏูˆุง vaccine with attenuated lymph virus
114
00:09:23,260 --> 00:09:29,700
ู„ุฃู†ู‡ it will lead to death patient have been
115
00:09:29,700 --> 00:09:32,260
classified according to the following figure or
116
00:09:32,260 --> 00:09:40,020
table ุฌุงุก ูˆุฏูˆุง ู‚ุณู…ู‡ู… ู„ T minus B plus T minus B
117
00:09:40,020 --> 00:09:45,920
minus ุฃู†ูˆุงุน ู…ุฎุชู„ูุฉ ุณู†ุชุทุฑู‚ ู„ูƒู„ ู†ูˆุน ู…ู† ู‡ุฐู‡ ุงู„ุฃู†ูˆุงุน ุจุณ
118
00:09:45,920 --> 00:09:51,980
ูŠุฌุจ ุฃู† ู†ูู‡ู… ุงู† T minus ูŠุนู†ูŠ ููŠ ุบูŠุงุจ ู„ T cell ุจูŠ
119
00:09:51,980 --> 00:09:57,500
ุจู„ุณ ูŠุนู†ูŠ ููŠ normal ุจูŠ cell ูˆ ู…ู…ูƒู† ูŠูƒูˆู† ููŠ ุบูŠุงุจ
120
00:09:57,500 --> 00:10:02,280
ู„ NK cell ู„ู…ุง ุฃู‚ูˆู„ T minus ุจูŠ minus ูŠุนู†ูŠ ู„ุง ุจูŠ
121
00:10:02,280 --> 00:10:08,780
ูˆู„ุง T cell ู…ูˆุฌูˆุฏุฉ ูˆ ู„ู…ุง ุฃู‚ูˆู„ ุงู„ุงุซู†ูŠู† plus ู…ุนู†ุงุชู‡
122
00:10:08,780 --> 00:10:12,080
ุงู„ู†ุงุณ ุงู„ุชุงู†ูŠุฉ ู‡ุฏูˆู„ ุนู†ุฏู‡ู… T cell ูˆ B cell ู„ูƒู† ู‡ู… ุบูŠุฑ
123
00:10:12,080 --> 00:10:18,840
ุดุบุงู„ูŠู† ู…ุด ุดุบุงู„ูŠู† T plus B minus it's very rare ูˆ
124
00:10:18,840 --> 00:10:23,960
they preferred treatment ุทุจุนุง ู„ุญุงู„ุงุช ู…ู† ู‡ุงู„ู†ูˆุน ุงู†ู‡
125
00:10:23,960 --> 00:10:28,460
ู†ุนู…ู„ bone marrow transplantation from an HLA
126
00:10:28,460 --> 00:10:33,660
matched sibling donor ูˆุฏู‡ ุจู‚ู‰ ูˆู‡ุฐู‡ ุงู„ุญุงู„ุงุช ุฃูˆู„ู‹ุง
127
00:10:33,660 --> 00:10:38,340
ุญุงู„ุฉ ู‡ูŠ T minus B plus ุงุชูู‚ู†ุง ุนู„ู‰ ุฃู†ู‡ ู‡ูŠ ู…ุง ููŠู‡ุงุด D
128
00:10:38,340 --> 00:10:42,000
-cell ูˆุฅู†ู…ุง ู…ุง ููŠู‡ B-cell ุงู„ู…ุฑุถ ู‡ุฐุง ุนุจุงุฑุฉ ุนู† X
129
00:10:42,000 --> 00:10:49,920
-linked skid ุจูŠู…ุซู„ 40 ู„ 50% ู…ู† ุงู„ุญุงู„ุงุช ุงู„ู„ูŠ ุจู†ุญูƒูŠ
130
00:10:49,920 --> 00:10:54,000
ุนู†ู‡ุง ุงู„ mutation ุฌุงู„ู‡ ู…ูˆุฌูˆุฏ ุนู„ู‰ ุงู„ X-chromosome
131
00:10:54,000 --> 00:10:58,980
ุงู„ุฌูŠู† ุงู„ู„ูŠ ุตุงุฑ ููŠู‡ mutation ู…ูˆุฌูˆุฏ ุนู„ู‰ ุงู„ X
132
00:10:58,980 --> 00:11:05,180
-chromosome which could for gamma chain ู…ุงุดูŠ
133
00:11:06,650 --> 00:11:12,870
Gamma Chain Cytokine Receptor ูˆุทุจุนู‹ุง this Gamma
134
00:11:12,870 --> 00:11:17,230
Chain ุชู„ุนุจ ุฏูˆุฑ ูƒุจูŠุฑ ููŠ ุงู„ู€ ุงู„ู„ูŠ ู‡ูˆ Signal
135
00:11:17,230 --> 00:11:22,290
Transduction ู„ุนุฏุฏ ูƒุจูŠุฑ ู…ู† ุงู„ Cytokine ู…ู†ู‡ุง IL2,
136
00:11:22,390 --> 00:11:30,110
IL4, IL7, IL9, IL15 ูˆุทุจุนุง ู‡ุฐู‡ ู…ุนู†ุงุชู‡ ุบูŠุงุจู‡ุง ุจูŠุนู…ู„
137
00:11:30,110 --> 00:11:36,930
ุบูŠุงุจ ู„ู€ ุงู„ function for this cytokine ูˆู‡ุฐุง ููƒุฑุฉ
138
00:11:36,930 --> 00:11:42,830
ูˆุงุถุญ ุฌุฏุง ู‡ูŠ Receptor ุงู„ู„ูŠ ู‡ูˆ ุนุจุงุฑุฉ ุนู† ุฅูŠุด ligand
139
00:11:42,830 --> 00:11:49,870
ู„ูƒู„ ุงู„ Cytokine ู‡ุฐูˆู„ ุงู„ ligand ุชุนูˆู†ูˆู‡ ู„ูƒู„ ุงู„
140
00:11:49,870 --> 00:11:55,690
Cytokine ู‡ุฐูˆู„ ูู‡ูŠ ุจุชุชูƒูˆู† ู…ู† two chain ูˆุงุญุฏุฉ ู…ู†ู‡ู…
141
00:11:55,690 --> 00:11:58,550
ุจุชู„ุนุจ ุฏูˆุฑ ูƒุจูŠุฑ ููŠ ุงู„ู€
142
00:11:58,550 --> 00:12:03,010
signal transduction ูˆู‡ูŠ ุงู„ gamma chain gamma chain
143
00:12:03,010 --> 00:12:05,690
ูˆุจุงู„ุชุงู„ูŠ ุบูŠุงุจู‡ุง ูŠุนู†ูŠ ู…ุง ููŠุด signal transduction
144
00:12:05,690 --> 00:12:10,270
ูˆุจุงู„ุชุงู„ูŠ ู…ุง ููŠุด transcription for this gene ู…ุงุดูŠ
145
00:12:10,270 --> 00:12:16,330
ูˆุจุงู„ุชุงู„ูŠ ูƒู„ ุงู„ function ู„ู‡ุฐู‡ ุงู„ Cytokine will be
146
00:12:16,330 --> 00:12:22,950
missed ุงู„ู…ุฑุถ
147
00:12:22,950 --> 00:12:30,260
ุงู„ุชุงู†ูŠ ุงู„ which ูŠุนู†ูŠ similar to this disease ู‡ูˆ
148
00:12:30,260 --> 00:12:34,880
ุบูŠุงุจ ุงู„ุฌุฒุก ุงู„ุชุงู†ูŠ ู…ู† ุงู„ Receptor ู…ุด ูƒู€ ุจูˆู„ูŠุจูŠุจุจุชูŠุฏ
149
00:12:34,880 --> 00:12:39,000
ุดูŠู†ูˆ ุฅู†ู…ุง ูƒู€ functioning process ุงู„ู„ูŠ ู‡ูˆ ุบูŠุงุจ ุงู„ู€ JAK
150
00:12:39,000 --> 00:12:44,900
ูŠูˆู… ู…ุง ูŠุตูŠุฑ ููŠู‡ ุบูŠุงุจ ู„ู„ู€ JAK ุทุจุนุง ู…ุง ูŠุตูŠุฑุด ููŠู‡ ุชุบูŠุฑ
151
00:12:44,900 --> 00:12:47,440
ููŠ ุงู„ Gamma ูˆู…ุชู…ุง ุชุบูŠุฑุช ุจุชุงุนุฉ ุงู„ Signal
152
00:12:47,440 --> 00:12:52,190
transduction ุบูŠุงุจ ุงู„ู€ JAK ุฃูŠุถุง ุจุฑุถู‡ ุจูŠุนู…ู„ ู†ูุณ ุงู„ุฃุนุฑุงุถ
153
00:12:52,190 --> 00:12:57,950
ูˆุจุงู„ุชุงู„ูŠ ุจูŠุตูŠุฑ ููŠู‡ ุบูŠุงุจ ู„ู„ู€ signal transduction ู‡ุฐุง
154
00:12:57,950 --> 00:13:04,990
X-linked ูˆุงู„ู€ JAK deficiency ู‡ูˆ ุนุจุงุฑุฉ ุนู† ุงุชุฒูˆู… ุงู„ู€
155
00:13:04,990 --> 00:13:12,290
recessive disease ุฃูŠ
156
00:13:12,290 --> 00:13:15,670
ุงุชุฒูˆู… ุงู„ู€ recessive ู‚ู„ู†ุง ุบูŠุงุจ ุงู„ู€ JAK ุชู„ุงุชุฉ ู‡ูˆ
157
00:13:15,670 --> 00:13:21,290
ุนุจุงุฑุฉ ุนู† Tyrosine Kinase ูˆุทุจุนุง ุบูŠุงุจู‡ ุจูŠุนู†ูŠ ู…ุง ููŠุด
158
00:13:21,290 --> 00:13:24,950
signal transduction ูˆูˆุฌุฏูˆุง ุฃู† ุงู„ expression of
159
00:13:24,950 --> 00:13:28,530
JAK ู…ูˆุฌูˆุฏ ููŠ ูƒู„ ุงู„ู€ hemopoietic cells ูˆุจุงู„ุชุงู„ูŠ
160
00:13:28,530 --> 00:13:33,790
ู…ุง ูŠุตูŠุฑุด ููŠ maturation ู„ู„ุฎู„ุงูŠุง
161
00:13:33,790 --> 00:13:40,310
ู‡ุฐู‡ ุงู„ู†ู‚ุทุฉ ุงู„ุชุงู†ูŠุฉ T minus B minus ูˆู…ู† ุงู„ุฃู…ุฑุงุถ
162
00:13:40,310 --> 00:13:46,830
ุงู„ู…ุดุงุฑูƒุฉ ููŠ ู‡ุฐุง ุงู„ู€ group ู‡ูˆ ุงู„ adenosine deaminase
163
00:13:46,830 --> 00:13:52,160
deficiency ูˆู‡ุฐุง ุนุจุงุฑุฉ ุนู† ุฅู†ุฒูŠู… ุจูŠู„ุนุจ ุฏูˆุฑ ูƒุจูŠุฑ ููŠ
164
00:13:52,160 --> 00:13:59,660
ุงู„ู€ Purine pathway ูŠู…ุซู„ 20% ู…ู† ุญุงู„ุงุช ุงู„ู€ Skid ูˆู‡ูˆ
165
00:13:59,660 --> 00:14:05,260
ุนุจุงุฑุฉ ุนู† autosomal recessive disease ูˆุบูŠุงุจู‡ ุจูŠุนู†ูŠ
166
00:14:05,260 --> 00:14:11,720
accumulation of toxic wastes ุจูŠุตูŠุฑ ููŠ build up ููŠ
167
00:14:11,720 --> 00:14:20,200
build up ู„ูŠุด ู„ู„ู€ toxic waste ููŠ ุงู„ุฌุณู… ุทุจุนุง it has
168
00:14:20,200 --> 00:14:24,340
greatest impact of the immune ุนู„ู‰ ุงู„ุฌู‡ุงุฒ ุงู„ู…ู†ุงุนูŠ
169
00:14:24,340 --> 00:14:29,880
ุจูŠุคุฏูŠ ู„ู€ failure ุฃูˆ both T and B cell development ุจุนุฏ
170
00:14:29,880 --> 00:14:32,260
ุชุงู†ู‰ ุงู„ู„ูŠ ู‡ูˆ purely nucleotide phosphorylase
171
00:14:32,260 --> 00:14:33,020
deficiency
172
00:14:35,470 --> 00:14:39,610
ู‡ุฐุง ุณูŠุคุฏูŠ ุฃูŠุถู‹ุง ุฅู„ู‰ ุจู†ุงุก ุชุฌุงุฑุจ ู…ู† ุฃุฌู‡ุฒุฉ ู…ุฎุงุทุฑุฉ
173
00:14:39,610 --> 00:14:47,910
ุฎุตูˆุตู‹ุง ู‡ุฐู‡ ุงู„ุฃุฌู‡ุฒุฉ ุงู„ู…ุฎุงุทุฑุฉ ุจุฅู…ูƒุงู†ู‡ุง ุชุฏู…ุฑ ู†ุธุงู…
174
00:14:47,910 --> 00:14:52,930
ุงู„ู‡ูŠู…ูˆู„ูˆุฌูŠ ูˆุจูŠุฃุซุฑ
175
00:14:52,930 --> 00:14:57,570
ุฃูŠุถู‹ุง ุนู„ู‰ ุงู„ู€ T-cell ูˆุจุงู„ุชุงู„ูŠ ูƒู„ ุงู„ู€ lymphocytes
176
00:14:57,570 --> 00:15:03,470
ู…ุฏูู†ูŠู† ู†ูˆุน ุชุงู†ูŠ ุงู„ู„ูŠ ู‡ูˆ Recombinase deficiency
177
00:15:04,630 --> 00:15:09,150
ุฃูŠุถู‹ุง ุงู„ู€ Recombinase Deficiency ู†ุนุฑู ุฃู†ู‡ ููŠ
178
00:15:09,150 --> 00:15:13,610
ุงู„ุฌูŠู†ุงุช ุงู„ู…ุณุคูˆู„ุฉ ุงู„ู„ูŠ ู‡ูŠ RAG 1 ูˆ RAG 2 ู‡ู…ุง two
179
00:15:13,610 --> 00:15:16,750
important genes ู…ูˆุฌูˆุฏูŠู† ููŠ ุงู„ู€ lymphocytes only
180
00:15:16,750 --> 00:15:21,710
ูˆุจูŠู„ุนุจูˆุง ุฏูˆุฑ ูƒุจูŠุฑ ููŠ ุงู„ู€ rearrangement of both
181
00:15:21,710 --> 00:15:28,950
immunoglobulin gene and TCR gene ูˆุจุงู„ุชุงู„ูŠ ุบูŠุงุจู‡ู…
182
00:15:29,520 --> 00:15:34,520
ุจูŠุคุฏูŠ ุฅู„ู‰ ุฎู„ู„ ููŠ ุงู„ู€ gene rearrangement ูˆุจุงู„ุชุงู„ูŠ
183
00:15:34,520 --> 00:15:38,600
ุงู„ู€ mutation ุจุชุคุซุฑ ุฅู„ู‰ complete absence ุชุนู…ู„
184
00:15:38,600 --> 00:15:43,440
complete absence ู„ู„ู€ T ูˆ B lymphocytes ูˆุจุงู„ุชุงู„ูŠ
185
00:15:43,440 --> 00:15:44,540
ู…ุง ููŠุด immunoglobulins
186
00:15:50,790 --> 00:15:56,210
ูˆุจุงู„ุชุงู„ูŠ ู…ุง ููŠุด match or ู„ุฃ ุชูŠ ูˆู„ุง ุจูŠ ู„ุฃู† ุงู„ู€
187
00:15:56,210 --> 00:16:04,670
function is intact ุชูŠ ุจู„ุณ ุจูŠ ู…ุง ุนุฏุง ุฅุฐุง ุจูŠู‚ูˆู„ูˆุง
188
00:16:06,040 --> 00:16:10,740
ูˆู‚ุงู„ูˆุง ุฅู† ุฃุดุงุฑู‡ุง ุงู„ู€ Omen Syndrome ูˆุงู„ู€ Omen
189
00:16:10,740 --> 00:16:17,280
Syndrome ุฃูŠุถู‹ุง ู‡ูˆ ุนุจุงุฑุฉ ุนู† ุฎู„ู„ ุจูŠุตูŠุฑ ููŠู‡ reduction
190
00:16:17,280 --> 00:16:21,420
ููŠ ุงู„ู€ or partial complete or partial reduction of
191
00:16:21,420 --> 00:16:27,900
the RAG genes ูˆุจุงู„ุชุงู„ูŠ ุจูŠุตูŠุฑ ููŠู‡ ุฎู„ู„ ููŠ ุงู„ู€ RAG
192
00:16:27,900 --> 00:16:32,760
activity ุงู„ู€ clinical presentation ุฒูŠ ูˆุฒูŠ ุงู„ู€ graft
193
00:16:32,760 --> 00:16:39,350
versus host disease ูˆุงู„ู†ุงุณ ุฏูˆู„ุฉ ุชุฏูุน ู‡ุฐู‡ ุงู„ุชุญูƒู…ุงุช
194
00:16:39,350 --> 00:16:44,390
ู„ู„ู†ุธุงู… ุงู„ู…ู†ุงุนูŠ ูˆู‡ู… ู„ุฏูŠู‡ู… ุฌุณุฏ ูƒุจูŠุฑ ุฌูŠ ุชูŠ
195
00:16:44,390 --> 00:16:51,550
infiltration ู…ู† ุฒูŠู†ูˆููŠู„ ูˆactivated T cell ุชุฏูุนู†ุง ุงู„ู€
196
00:16:51,550 --> 00:16:57,290
hyper immunoglobulin production of cytokine ูˆู‡ุฐุง ุจูŠู‚ุฏุฑ ุงู„ู€ hyper IgE
197
00:16:57,290 --> 00:17:00,730
syndrome ูˆ Job syndrome
198
00:17:03,450 --> 00:17:08,590
ุงู„ุฎู„ุงุตุฉ ู…ุฑุถู‰ ู…ู† ู‡ุฐุง ุงู„ู†ูˆุน ุจูŠุญุชุงุฌ ุงู„ู‰ pre
199
00:17:08,590 --> 00:17:14,430
-treatment with immunosuppressive drug ุงู„ู€
200
00:17:14,430 --> 00:17:21,550
T plus B plus subgroup ูƒู„ ุงู„ุชู†ุชูŠู† ู…ูˆุฌูˆุฏูŠู† ู„ูƒู† they
201
00:17:21,550 --> 00:17:24,870
are not functioning ุฃุดู‡ุฑ ู‡ุฐู‡ ุงู„ุฃู…ุฑุงุถ ุงู„ู€ bare
202
00:17:24,870 --> 00:17:30,040
lymphocyte syndrome ุฏู‡ ู‡ูˆ ุจูŠุคุฏูŠ ุงู„ู‰ results from
203
00:17:30,040 --> 00:17:34,920
the failure to express HLA molecule ูˆุงู„ุณุจุจ ููŠ ุฐู„ูƒ
204
00:17:34,920 --> 00:17:37,960
ุทุจุนุง ู…ุง ููŠุด HLA molecule ูŠุนู†ูŠ ู…ุง ููŠุด antigen
205
00:17:37,960 --> 00:17:45,220
presentation ุจูˆุงุณุทุฉ ุทุจุนุง ุงู„ู„ูŠ ู‡ูˆ HLA class 2
206
00:17:45,220 --> 00:17:48,680
molecule deficiency ููŠ ุงู„ุบุงู„ุจ class 1 ู…ู…ูƒู† ูŠูƒูˆู†
207
00:17:48,680 --> 00:17:54,470
ู…ุชุฃุซุฑ ูˆู…ู…ูƒู† ู„ู€ circulating T and B cell may be
208
00:17:54,470 --> 00:18:00,110
normal ู„ูƒู† ููŠ ุบูŠุงุจ ุงู„ู€ HLA class 2 molecule ู…ุง
209
00:18:00,110 --> 00:18:07,180
ุจูŠุญุตู„ ููŠู‡ antigen presentation ู„ู€ CD4 T cell ุงู„ู€ ZAP
210
00:18:07,180 --> 00:18:12,080
-70 mutation ู‡ูŠ ุนุจุงุฑุฉ ุนู† ูƒูŠู…ูŠูƒุงู„
211
00:18:12,080 --> 00:18:19,620
ู…ูŠุณู†ุฌุฑ ุจูŠุนู…ู„ ู†ู‚ู„ ู„ู„ุฅุดุงุฑุฉ ุจู…ู†ุฎุฏ
212
00:18:19,620 --> 00:18:21,700
TCR ู„ู„ู†ูˆูƒู„ูŠุงุณ ูˆู‡ูˆ ู†ู‚ู„ ู„ู„ุฅุดุงุฑุฉ ุจู…ู†ุฎุฏ TCR ู„ู„ู†ูˆูƒู„ูŠุงุณ
213
00:18:21,700 --> 00:18:24,800
ูˆู‡ูˆ ู†ู‚ู„ ู„ู„ุฅุดุงุฑุฉ ุจู…ู†ุฎุฏ TCR ู„ู„ู†ูˆูƒู„ูŠุงุณ ูˆู‡ูˆ ู†ู‚ู„
214
00:18:24,800 --> 00:18:27,880
ู„ู„ุฅุดุงุฑุฉ
215
00:18:27,880 --> 00:18:31,840
ุจู…ู†ุฎุฏ TCR ู„ู„ู†ูˆูƒู„ูŠุงุณ ุดูˆููˆุง ู‡ุฐู‡ ุงู„ุนู„ุงู‚ุฉ ู…ุง ุฃุญู„ุงู‡ุง
216
00:18:31,840 --> 00:18:37,580
ู†ุนุฑู ุฃู†ู‡ ููŠ ุนู†ุฏู†ุง antigen presenting cell ู…ุงุดูŠ
217
00:18:37,580 --> 00:18:43,160
ุจุชู‚ุฏู… ุงู„ู„ูŠ ู‡ูˆ
218
00:18:43,160 --> 00:18:47,400
antigen
219
00:18:47,400 --> 00:18:56,040
ุงู„ู€ antigen ู„ู€ T-lymphocyte ูˆุทุจุนู‹ุง ุณูˆุงุก ูƒุงู†ุช ุงู„ู€
220
00:18:56,040 --> 00:19:01,140
Antigen Presenting Cell Macrophage ุฃูˆ B Cell ุชู†ุชู‡ูŠ
221
00:19:01,140 --> 00:19:05,660
ุจู‚ุฏู… ุงู„ุงู†ุชูŠุฌู† ู„ู…ู†ุŸ ู„ู€ T-Lymphocyte ุดูˆููˆุง ุงุญุชู…ุงู„ุงุช
222
00:19:05,660 --> 00:19:09,340
ุงู„ุฎู„ู„ ูƒูŠู ุจุชุตูŠุฑ ู‚ุจู„ ุงุญุชู…ุงู„ ูŠุตูŠุฑ ููŠู‡ ุฎู„ู„ ููŠ ุงู„ู€
223
00:19:09,340 --> 00:19:13,220
MHC Class II ุจูŠุนู…ู„ ู…ุฑุถ ูŠุณู…ูˆู†ู‡ Bare Lymphocyte
224
00:19:13,220 --> 00:19:16,740
Syndrome ุญุงุฌุฉ ู†ู‚ุงู„ ู…ุชูˆู… ุงุญุชู…ุงู„ ุงู„ุฎู„ู„ ูŠูƒูˆู† ููŠ ุงู„ู€
225
00:19:16,740 --> 00:19:20,860
FAS ุฃูˆ ุงู„ู€ FAS ligand ูˆ ู‡ูŠุนู…ู„ FAS Deficiency
226
00:19:20,860 --> 00:19:27,110
Syndrome ูˆุงุญุชู…ุงู„ ุงู„ุฎู„ู„ ูŠูƒูˆู† ููŠ CD40 ligand ูˆ CD40
227
00:19:27,110 --> 00:19:30,590
ligand ู…ูˆุฌูˆุฏ ุนู„ู‰ ุงู„ู€ T cell ุจูŠุนู…ู„ ุญุงุฌุฉ ุจูŠุณู…ูˆู‡ุง
228
00:19:30,590 --> 00:19:37,990
Hyper IgM Syndrome ุฃุซุฑ
229
00:19:37,990 --> 00:19:43,150
Multi System Disorders ุจุงู„ุฅุถุงูุฉ ู„ู„ู€ SCID ููŠ SCID
230
00:19:43,150 --> 00:19:48,190
like clinical picture associated with certain
231
00:19:48,190 --> 00:19:52,000
disease ุฒูŠ Wiskott-Aldrich Syndrome ูˆุฏู‡ ุงุณู…ู‡
232
00:19:52,000 --> 00:19:56,940
syndrome ุนุจุงุฑุฉ ุนู† X-linked disease ุจูŠุชู…ุซู„ ุจุงู„ู‚ุงุชู„
233
00:19:56,940 --> 00:20:00,860
ุฑู‚ู… ูˆุงุญุฏ ููŠ bleeding ู„ุฃู†ู‡ ููŠู‡ thrombocytopenia
234
00:20:00,860 --> 00:20:04,340
ุฑู‚ู… ุงุซู†ูŠู† ููŠ recurrent bacterial infection ููŠ
235
00:20:04,340 --> 00:20:12,200
allergic reaction ููŠ long term patient ู…ู…ูƒู† ูŠุฌู„ุจ ู„ู€
236
00:20:12,200 --> 00:20:18,680
malignant disease ูˆุงู„ู€ genetic basis ูŠุนู†ูŠ
237
00:20:18,680 --> 00:20:24,580
mutation ููŠ ุงู„ู€ X-linked gene ุงู„ู„ูŠ ุจูŠุคุฏูŠ ุงู„ู‰ a
238
00:20:24,580 --> 00:20:29,940
which code for ูˆูŠุณูƒูˆุช ุฃู„ุฏุฑูŠุฎ ุณู†ุฏุฑูˆู… ุจุฑูˆุชูŠู† ูˆู‡ุฐุง
239
00:20:29,940 --> 00:20:35,400
ู…ูˆุฌูˆุฏ ููŠ ูƒู„ ุงู„ู€ hemopoietic stem cells both T and
240
00:20:35,400 --> 00:20:38,220
B cell are functionally non-abnormal
241
00:20:40,700 --> 00:20:47,340
ูˆุจุงู„ุชุงู„ูŠ ู„ุง ูŠู…ูƒู† ู„ู„ุดุฎุต ุฃู† ูŠุชูุงุนู„ ุจู€ Polysaccharide
242
00:20:47,340 --> 00:20:51,640
Antigen ุงู„ุชุนุงู…ู„ ููŠ ู‡ุฐู‡ ุงู„ุญุงู„ุฉ ูŠุญุชุงุฌ ุฅู„ู‰ Antibiotic
243
00:20:51,640 --> 00:20:57,600
ูˆ Antiviral ูˆ Bone marrow transplantation ูˆุจุฏูˆู† ู‡ุฐุง
244
00:20:57,600 --> 00:21:02,260
ุงู„ุนู„ุงุฌ ุงู„ู€ life expectancy ู„ุง ุชุชุนุฏู‰ ุชู„ุช ุณู†ูˆุงุช
245
00:21:02,260 --> 00:21:09,180
ุฃุชุงูƒุณูŠุง ุชู„ุงู†ุฌูŠูƒุชุงุฒูŠุง ู…ู† ุงู„ู‚ุตูŠุฑ ุจุฑุถู‡ ู…ุฑุถู‰ system
246
00:21:09,180 --> 00:21:14,320
genetic disorders ุจูŠุชู…ุซู„ ุจุงู„ู‚ุงุชู„ ุจูŠุตูŠุฑ ููŠู‡ jerky
247
00:21:14,320 --> 00:21:19,480
movement or lack of muscle coordination ูˆู†ู…ุฑ ุงุซู†ูŠู†
248
00:21:19,480 --> 00:21:24,170
abnormal vascular dilatation ุชู„ุงู†ุฌูŠูƒุชุงุฒูŠุฉ ููŠ ุงู„ู€ eye
249
00:21:24,170 --> 00:21:28,570
ูˆุงู„ู€ skin ูˆ ุจุฒูŠุงุฏุฉ ุงู„ susceptibility to infection
250
00:21:28,570 --> 00:21:34,870
ุจูŠุตูŠุฑ ู„ู†ููˆู…ุฉ ูˆุงู„ู€ defect ููŠ ุงู„ู€ both B ูˆ T cell
251
00:21:34,870 --> 00:21:40,270
ุงู„ gene ุทุจุนุง of ataxia telangiectasia codes for a
252
00:21:40,270 --> 00:21:46,490
protein known as ATM. ุงู„ุฃุทูุงู„ have a risk for
253
00:21:46,490 --> 00:21:51,870
developing malignancy ุฎุตูˆุตุง ุงู„ lymphoid neoplasm
254
00:21:55,810 --> 00:22:01,390
ุงู„ู€ category ุงู„ุซุงู†ูŠ ู‡ูˆ ุงู„ immune deficiency
255
00:22:01,390 --> 00:22:04,030
disorder associated with T cell and cell-mediated
256
00:22:04,030 --> 00:22:08,510
immunity. ู‚ุงู„ูˆุง ุงู„ู†ุงุณ ู‡ุฏูˆู„ุฉ ู…ุด ุนู†ุฏู‡ู… T cell
257
00:22:08,510 --> 00:22:12,790
associated deficiency disease. ุฅู†ู‘ู‡ ุงุชูู‚ู†ุง ุนู„ู‰ ุฃู† ุงู„
258
00:22:12,790 --> 00:22:19,090
T cell deficiency ู…ุงู‡ูŠุด associated with ุงู„ู„ูŠ ู‡ูˆ
259
00:22:19,090 --> 00:22:21,810
disease ุฒูŠ ุงู„ viral, fungal, protozoal infection
260
00:22:23,590 --> 00:22:26,890
ูˆูƒู„ู†ุง ุจู†ุนุฑู ุฅู† ุงู„ู€ T-Lymphocyte ุจุชุณุงุนุฏ ุงู„ู€ B
261
00:22:26,890 --> 00:22:30,730
-Lymphocyte ููŠ ุฅู†ุชุงุฌ ุงู„ู€ antibody, which antibody
262
00:22:30,730 --> 00:22:36,430
would form T cell dependent antigen. ูˆุบูŠุงุจ or T
263
00:22:36,430 --> 00:22:40,810
cell associated deficiency ู‡ูŠุนู…ู„ selective defect
264
00:22:40,810 --> 00:22:46,170
in antibody production. ูˆุจุงู„ุชุงู„ูŠ T cell deficient
265
00:22:46,170 --> 00:22:51,430
patient have difficulty to distinguish, have
266
00:22:51,430 --> 00:22:55,850
difficulty to distinguish clinically to be
267
00:22:55,850 --> 00:23:00,270
distinguished clinically from a septic patient. ู…ุง
268
00:23:00,270 --> 00:23:05,450
ุฒุงู„ ุงู„ B ูˆ ุงู„ T ู…ุด ู…ูˆุฌูˆุฏุฉ ูŠุจู‚ู‰ ูƒู…ุงู† ุงู„ B ู…ุด ุฑุงุญ
269
00:23:05,450 --> 00:23:09,350
ุชุดุชุบู„. Congenital
270
00:23:09,350 --> 00:23:13,890
Thymic Aplasia ุงู„ู„ูŠ ู‡ูˆ ุฏูŠุฌูˆุฑุฌ ุณู†ุฏุฑูˆู…. ู‚ู„ู†ุง ู‡ุฐุง ููŠ
271
00:23:13,890 --> 00:23:20,950
ู…ุฑุงุญู„ ู…ุจูƒุฑุฉ ุฌุฏุง ุจุตูŠุฑ ุฅุฐุง ูุงูƒุฑูŠู† ููŠ ุฑู‚ู… ุงุชู†ูŠู† ููŠ ุงู„ู€
272
00:23:20,950 --> 00:23:26,110
T cell hemopoietic maturation steps. ุงู„ู…ู‡ู… ุฏูŠ ุฌูˆุฑุฌ
273
00:23:26,110 --> 00:23:31,070
ุณู†ุฏุฑูˆู… ุจูŠุนู†ูŠ ุงู†ู‡ ููŠู‡ T cell deficiency ูˆ in which
274
00:23:31,070 --> 00:23:34,770
the cells must develop abnormally. ู…ุงููŠุด ุงูŠุด ู…ุงููŠุด
275
00:23:34,770 --> 00:23:38,950
development. ูŠุจู‚ู‰ ู…ุงููŠ ุฅู†ุชุงุฌ ู„ T lymphocyte. no T
276
00:23:38,950 --> 00:23:46,310
cell ูˆ ู†ู‚ูˆู„ ุฅู† ุงู„ุฎู„ู„ ู†ุงุชุฌ ุนู† defective migration
277
00:23:46,310 --> 00:23:51,420
of fetal neural crest cells. ุงู„ุซุงู„ุซุฉ ูˆุงู„ุชุงู„ุชุฉ
278
00:23:51,420 --> 00:23:58,280
ู…ุตุทู„ุญุงุช ุงู„ูุฑู†ุฌูŠุงู„. ูˆุจุงู„ุชุงู„ูŠ ุงู„ู…ุฑูŠุถ ุงู„ู‡ุงุฑุฏ ูˆุงู„ููŠุณ
279
00:23:58,280 --> 00:24:05,480
ูŠุชุทูˆุฑ ุจุดูƒู„ ุทุจูŠุนูŠ ูˆุจุฑุถู‡ ุงู„ุซุงูŠู…ุณ ูˆุงู„ุจุฑุงุซูŠุฑูˆูŠุฏ ู„ุง ูŠุชู…
280
00:24:05,480 --> 00:24:08,820
ุชูƒูˆูŠู†ู‡ุง. ู‡ุฐุง ูŠุคุฏูŠ ุฅู„ู‰ ุซุงูŠู…ูƒ ุฃุจู„ูŠุฌูŠุง
281
00:24:08,820 --> 00:24:14,640
ูˆhypoparathyroidism. ุซุงูŠู…ูƒ
282
00:24:14,640 --> 00:24:18,940
ุฃุจู„ูŠุฌูŠุง ูŠู†ุชู‡ูŠ ููŠ ู…ูุงุฌุฃุฉ ู…ุฏุฑุณุฉ ู…ุฏุฑุณุฉ ู…ุฏุฑุณุฉ ู…ุฏุฑุณุฉ
283
00:24:19,890 --> 00:24:24,170
DiGeorge's syndrome ู‡ูˆ ู…ุด hereditary disease ูˆุงู†ู…ุง
284
00:24:24,170 --> 00:24:31,990
ุจูŠุตูŠุฑ ููŠู‡ Sporadic deficiency in chromosome 22q11
285
00:24:31,990 --> 00:24:36,990
or deletion. ุทุจุนุง ู‡ุฏูˆู„ ุงู„ู…ุฑุถู‰ ุจูŠุตูŠุฑ ููŠ ุนู†ุฏู‡ู…
286
00:24:36,990 --> 00:24:40,350
recurrent or chronic infection with viruses
287
00:24:40,350 --> 00:24:47,810
ุจูƒุชูŠุฑูŠุง ูู†ุฌุงู‰ ุจุฑูˆุชูˆุฒูˆุง. ูˆ ุงู„ู†ุงุณ ู‡ุฏูˆู„ ุนู†ุฏู‡ู… ู‚ูŠุงุจ ู„ู„
288
00:24:47,810 --> 00:24:54,090
T cell.ุฃูŠุถู‹ุง ูุดู„ุช ุชุฌุฑูŠ ุนู„ู‰ ุชุฌุงุฑุจ ุงู„ุงู†ุชุจุงู‡ ู‡ุฐู‡
289
00:24:54,090 --> 00:24:56,730
ุงู„ุฃุดุฎุงุต ู„ุง ูŠุฌุจ ุฃู† ูŠูƒูˆู†ูˆุง ู…ู…ูŠุฒูŠู† ุจูˆุงุณุทุฉ ู…ูˆุงุฌู‡ุฉ
290
00:24:56,730 --> 00:24:58,610
ู…ูˆุงุฌู‡ุฉ ู…ูˆุงุฌู‡ุฉ ู…ูˆุงุฌู‡ุฉ ู…ูˆุงุฌู‡ุฉ ู…ูˆุงุฌู‡ุฉ ู…ูˆุงุฌู‡ุฉ ู…ูˆุงุฌู‡ุฉ
291
00:24:58,610 --> 00:25:02,910
ู…ูˆุงุฌู‡ุฉ ู…ูˆุงุฌู‡ุฉ ู…ูˆุงุฌู‡ุฉ
292
00:25:03,160 --> 00:25:06,740
with normal peripheral T cell number. ูŠุนู†ูŠ ููŠู‡
293
00:25:06,740 --> 00:25:12,140
normal T lymphocyte ู„ูƒู† ููŠ ู†ูุณ ุงู„ูˆู‚ุช ูุดูŠ ูุดูŠ
294
00:25:12,140 --> 00:25:17,960
function. ุงุฏู‰ functional defect ูู‰ T cell ุงูŠุถุง
295
00:25:17,960 --> 00:25:22,260
opportunistic infection and high incidence of
296
00:25:22,260 --> 00:25:27,140
autoimmune disease. ู…ู„ุงุญุธุงุช it's autosomal
297
00:25:27,140 --> 00:25:32,200
recessive pattern. ูˆุทุจุนุง ู‡ูˆ ุนุจุงุฑุฉ ุนู† heterogeneous
298
00:25:32,200 --> 00:25:38,880
group.ุฃูŠุถุง ูŠุดู…ู„ ุบูŠุงุจ ู„ู„ ZAP-17 tyrosine kinase. CD3E
299
00:25:38,880 --> 00:25:45,860
ูˆCD3G. ู‡ูˆ ู‡ุฐู‡ ุงู„ู…ูˆู„ูŠูƒูŠูˆู„ ุงู„ู…ุชุนู„ู‚ุฉ ุจุงู„ุฅุดุนุงุฑ T-cell
300
00:25:45,860 --> 00:25:55,840
ูˆุจุงู„ุชุงู„ูŠ ู…ุงููŠุด ูุงู†ูƒุดู†. Autoimmune
301
00:25:55,840 --> 00:26:01,920
lymphoproliferative disease. ุงูˆุฃูŠุถุงู‹ ุฅู†ู‡ุง ุชุณู…ู‰ ุจู€
302
00:26:01,920 --> 00:26:06,300
Inherited by Massive Proliferation of Lymphoid
303
00:26:06,300 --> 00:26:08,980
Tissue. ูˆุจุฏุฃุช
304
00:26:08,980 --> 00:26:27,160
ูŠุชุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุทุท
305
00:26:32,150 --> 00:26:35,050
ุนุงู…ู„ ุงู„ู€ autoimmune lymphoproliferative ุงู„ุดุฎุตูŠุฉ ุฃูˆ
306
00:26:35,050 --> 00:26:43,170
ุงู„ุดุฎุตูŠุฉ ุงู„ุณูŠู†ุงู…ูŠุฉ ู„ุฏูŠู‡ุง ู…ูŠูˆุชูŠุดู† ููŠ ุงู„ู€ FAS gene
307
00:26:43,170 --> 00:26:51,870
ูŠุชุนุงู…ู„ ู…ุน ุงู„ู€ FAS protein CD95. ูŠุชุนุงู…ู„ ู…ุน ุงู„ู€
308
00:26:51,870 --> 00:27:00,350
Apoptosis signaling. ู„ุฏูŠู‡ู… ูˆุงุญุฏ ุทุจูŠุนูŠ ูˆูˆุงุญุฏ ู…ูŠูˆุชูŠุช
309
00:27:00,350 --> 00:27:07,140
FAS molecule. ู‡ุฐุง ุจูŠุคุฏูŠ or that mutated phase
310
00:27:07,140 --> 00:27:11,140
molecule interferes with the function of normal
311
00:27:11,140 --> 00:27:15,780
molecule. ุทุจุนุง ุงู„ mutated ู‡ูˆ ุงู„ู„ูŠ ุจูŠุชุฏุฎู„ ููŠ ุงู„
312
00:27:15,780 --> 00:27:20,420
function of normal molecule. These patients have
313
00:27:20,420 --> 00:27:25,840
defect in other component of apoptosis pathway. ุฒูŠ
314
00:27:25,840 --> 00:27:29,120
ุงู„ Fas ligand or caspase 10
315
00:27:31,670 --> 00:27:37,270
Chronic Mucocutaneous Candidiasis. ุจูŠู‡ ู…ู† ุงู„ุงุณู…
316
00:27:37,270 --> 00:27:42,250
Candidiasis ูŠุนู†ูŠ ููŠู‡ Candida infection of skin and
317
00:27:42,250 --> 00:27:47,830
mucous membrane. ุบุงู„ุจุง ุงู„ู…ุฑุถู‰ have normal T cell
318
00:27:47,830 --> 00:27:52,070
mediated immunity to microorganism other than
319
00:27:52,070 --> 00:27:56,810
Candida and normal B cell mediated immunity to all
320
00:27:56,810 --> 00:28:04,190
microorganism ุจู…ุง ููŠู‡ุง ุงู„ Candida. ูŠุนู†ูŠ ุงู„ุฎู„ู„ ููŠ
321
00:28:04,190 --> 00:28:09,210
ุงูŠู‡ุŸ ููŠ ุงู„ T-lymphocyte which can respond to all
322
00:28:09,210 --> 00:28:12,930
the micro part ู…ุน ุงู„ Canada. ุจูŠู†ู…ุง ุงู„ B-lymphocyte
323
00:28:12,930 --> 00:28:17,350
is normal. They have selective defect in the
324
00:28:17,350 --> 00:28:20,210
function of T cell.
325
00:28:23,500 --> 00:28:28,520
ุงู„ุชุงู†ูŠ ู‡ูˆ ุงู„ BCR immunoglobulin associated
326
00:28:28,520 --> 00:28:33,400
immunodeficiency. ูˆุฃุดู‡ุฑ
327
00:28:33,400 --> 00:28:36,980
ู…ุซุงู„ ุนู„ู‰ ุฐู„ูƒ ุจุฑูˆุชูˆู† ุงูŠ ุฌุงู…ุง ุบู„ูˆุจูŠู„ุงู†ูŠู†ูŠุง. ูˆู‡ูˆ ุนุจุงุฑุฉ
328
00:28:36,980 --> 00:28:42,340
ุนู† X-linked infantile ุงูŠ ุฌุงู…ุง ุบู„ูˆุจูŠู„ุงู†ูŠู†ูŠุง. ุงู„ุฃุทูุงู„
329
00:28:42,340 --> 00:28:48,260
ู…ู† Infanta ุงู„ุฃุทูุงู„ present with serious, repeated
330
00:28:48,260 --> 00:28:52,390
infection. ูˆุณุจุจ ููŠ ุฐู„ูƒ is severe depression or
331
00:28:52,390 --> 00:28:56,710
virtual absence of all immunoglobulin. ู†ุญู†ุง ุจู†ุญูƒูŠ
332
00:28:56,710 --> 00:29:00,890
ุนู„ูŠู‡ุง ุจุฑูˆุชูŠู†ุฒ. ูŠุนู†ูŠ ู…ุงููŠุด ุจูŠ ุณู„ ู…ุงููŠุด ุงูŠุด ุจูŠ
333
00:29:00,890 --> 00:29:06,650
lymphocyte. ู…ุนู†ุงุชู‡ ู…ุงููŠุด antibody production. ุทุจุนุง
334
00:29:06,650 --> 00:29:11,250
ุงู„ major defect ูˆุฌุฏูˆู‡ ุงู†ู‡ ููŠ ุนุฏู… ู‚ุฏุฑุฉ ุงู„ุจูŠุช ุงู†ู‡ุง
335
00:29:11,250 --> 00:29:19,290
ุชุชุทูˆุฑ to be mature as B cell. ุจุฑูˆุชูŠู† ุฌูŠู†
336
00:29:20,990 --> 00:29:28,470
ุชู… ุชุบูŠูŠุฑู‡ ุจุทุฑูŠู‚ุฉ X ู…ุฑุชุจุทุฉ. ู‡ุฐู‡
337
00:29:28,470 --> 00:29:33,710
ุงู„ุฌูŠูˆุงู†ุงุช ุชุฏุนู‰ tyrosine kinase enzyme ู…ูˆุฌูˆุฏ ููŠ
338
00:29:33,710 --> 00:29:39,150
ุงู„ู€Cytosol. XLA
339
00:29:39,150 --> 00:29:44,810
ุชู… ุชุญูŠุทู‡ ู„ุนู‚ู„ ุนู‚ู„ูŠ ุงู„ู…ุชูˆุณุท ุงู„ู…ุชูˆุณุท
340
00:29:44,810 --> 00:29:46,210
ุงู„ู…ูˆุฌูˆุฏ ููŠ ุงู„ู€Cytoplasmic
341
00:29:49,190 --> 00:29:53,930
Patients suffer repeated infection. Treatment ุทุจุนุง
342
00:29:53,930 --> 00:29:57,490
Periodic injection of intravenous gamma globulin
343
00:29:57,490 --> 00:30:04,670
ุจูŠุญุชูˆูŠ ุนู„ู‰ IgG. Transient
344
00:30:04,670 --> 00:30:10,990
Hypo Gamma Globulinemia. ุงุณู… Transient ููŠ ุนู…ุฑ ุฎู…ุณุฉ
345
00:30:10,990 --> 00:30:16,940
ู„ุณุช ุดู‡ูˆุฑ. ุจูŠุตูŠุฑ ููŠู‡ Passively transferred from
346
00:30:16,940 --> 00:30:26,980
maternal to fetus of IgG antibody. ูˆุทุจุนุง
347
00:30:26,980 --> 00:30:36,140
ููŠ ู‡ุฐู‡ ุงู„ุญุงู„ุฉ ุจูŠุจุฏุฃ ุงู„ IGG ุจูŠุจุฏุฃ ูŠุธู‡ุฑ
348
00:30:36,140 --> 00:30:44,810
ุงู„ู„ูŠ ู‡ูˆ ุงู„ infant IgG. premature infant ู…ู…ูƒู† ูŠุตูŠุฑ
349
00:30:44,810 --> 00:30:49,570
ุนู†ุฏู‡ Transient IgG Deficiency if they are not yet
350
00:30:49,570 --> 00:30:55,050
able to synthesize immunoglobulin. Sometimes helper
351
00:30:55,050 --> 00:30:59,630
T cells are deficient. ูŠุนู†ูŠ ุจูŠุตูŠุฑ ููŠู‡ ุบูŠุงุจ ููŠ ุงู„ T
352
00:30:59,630 --> 00:31:04,030
lymphocyte help ูˆุจุงู„ุชุงู„ูŠ ู…ุงููŠุด Antibody production
353
00:31:04,030 --> 00:31:08,070
ุฃูˆ B cell functioning. ูŠุนู†ูŠ ู…ุงููŠุด ุดูŠุก. This disease
354
00:31:08,070 --> 00:31:10,310
may persist for a few months. ูˆ
355
00:31:12,600 --> 00:31:17,900
ุจุงู„ูƒุชูŠุฑ ู„ุบุงูŠุฉ ุณู†ุชูŠู†. It's not X-linked and should
356
00:31:17,900 --> 00:31:24,240
be distinguished from X-linked disease. ุฎู„ุงู„ ูˆุฌูˆุฏ
357
00:31:24,240 --> 00:31:29,460
ุงู„ normal number of B cells. Immunization should
358
00:31:29,460 --> 00:31:33,800
not be given during this period. Common variable
359
00:31:33,800 --> 00:31:38,120
immunodeficiency. ู…ู† ุงู„ุฅุณู… it's characterized by
360
00:31:38,120 --> 00:31:39,280
ุบูŠุงุจ
361
00:31:43,570 --> 00:31:51,510
ู…ุงุดูŠ or reduction in the serum IgG ูˆ IgA ูˆ ุจูŠูƒูˆู† ููŠ
362
00:31:51,510 --> 00:31:57,890
ุนู†ุฏู‡ IgM normal or low ูˆ ุทุจุนุง ููŠ normal or low
363
00:31:57,890 --> 00:32:03,950
number of B cell. ุงู„ B cell fails to mature
364
00:32:03,950 --> 00:32:09,650
into plasma cell.ูˆุงู„ู…ุฑุถู‰ have recurrent respiratory
365
00:32:09,650 --> 00:32:13,550
and gastrointestinal infection. Treatment by
366
00:32:13,550 --> 00:32:22,850
intravenous immunoglobulin. Selective
367
00:32:22,850 --> 00:32:29,160
immunoglobulin deficiency. ุงู„ู€ IgA-Deficiency ุบุงู„ุจุง
368
00:32:29,160 --> 00:32:31,860
ู…ุฑุถู‰ ุจุณ ูŠูƒูˆู† ุนู†ุฏู‡ู… recurrent viral or bacterial
369
00:32:31,860 --> 00:32:35,300
infection, celiac disease, defective absorption
370
00:32:35,300 --> 00:32:39,060
and repeal ุงู„ู„ูŠ ู‡ูˆ ุนุจุงุฑุฉ ุนู† ุงู„ู€ celiac or maybe
371
00:32:39,060 --> 00:32:43,720
entirely asymptomatic. Treatment ุจุฏู‡ pro-the
372
00:32:43,720 --> 00:32:47,360
spectrum antibiotic. IgM-Deficiency, rare
373
00:32:47,360 --> 00:32:52,300
disorder. ูˆุทุจุนุง ุงู„ู…ุฑุถู‰ ุจูŠุนุงู†ูˆุง ู…ู† recurrent and
374
00:32:52,300 --> 00:32:54,740
severe infection with polysaccharide antigen
375
00:32:54,740 --> 00:32:59,840
-encapsulated organism. ุฒูŠ pneumonia ุฃูˆ pneumococci
376
00:32:59,840 --> 00:33:05,040
and hemophilus inflammation ุงู„ disorders of T and
377
00:33:05,040 --> 00:33:11,780
B interaction ุฒูŠ ุงู„-hyper IgM syndrome ูˆู‡ูˆ ุนุจุงุฑุฉ ุนู†
378
00:33:11,780 --> 00:33:18,150
X-linked hyper IgM syndrome Present with
379
00:33:18,150 --> 00:33:22,530
recurrent respiratory infection ู…ู† ุฃูˆู„ ุณู†ุฉ ุฅู„ู‰
380
00:33:22,530 --> 00:33:27,670
ุณู†ุชูŠู† ู…ู† ุงู„ุนู…ุฑ ู…ูŠุชูŠุดู† ู…ูˆุฌูˆุฏุฉ ููŠ CD40-ligand gene
381
00:33:27,670 --> 00:33:32,010
ุงู„ู…ูˆุฌูˆุฏ ุนู„ู‰ ุงู„ู€ X chromosome ุงู„ู„ูŠ ูŠุจู‚ู‰ ุจูŠุคุฏูŠ ุฅู„ู‰
382
00:33:32,010 --> 00:33:37,890
CD40-ligand ูˆุจุงู„ุชุงู„ูŠ ููŠ ุงู„ุดูŠุก
383
00:33:40,910 --> 00:33:45,050
ุณูŠุฌู†ุงู„ ุชุฑุงู†ุฒุฏูƒุดู† ูŠุนู†ูŠ ู…ุงููŠุด ูุงู†ูƒุดู† ู„ู„ู€ CD40 ู„ูŠุฌุงู†ุฏ
384
00:33:45,050 --> 00:33:50,390
ุจุฑุช ู…ุน CD40 ู…ูˆุฌูˆุฏ ุนู„ู‰ ุณุทุญ ุงู„ู€ B lymphocytes ูˆุทุจุนุง this
385
00:33:50,390 --> 00:33:57,810
interaction rescues the B cell from apoptosis X
386
00:33:57,810 --> 00:34:00,990
-linked lymphoproliferative disease Duncan
387
00:34:00,990 --> 00:34:08,070
syndrome ูˆู‡ุฐู‡ ุจูŠุตูŠุฑ ููŠู‡ุง ุนุฏู… ู‚ุฏุฑุฉ ุนู†ุฏ ุงู„ู€ T cell to
388
00:34:08,070 --> 00:34:13,700
regulate B cell growth ูˆู‡ูˆ ุจูŠุนุชุจุฑ major part of the
389
00:34:13,700 --> 00:34:19,820
underlying disease
390
00:34:19,820 --> 00:34:24,220
ูŠุนู†ูŠ this mechanism deficiency ู‡ูˆ ุงู„ุฃุณุงุณ ููŠ
391
00:34:24,220 --> 00:34:29,730
ุงู„ู…ูˆุถูˆุน lymphoma incidence is high ูˆุงู†ุชู‚ู„ ู„ู„ู€
392
00:34:29,730 --> 00:34:35,090
phagocytic function ูู‚ุท
393
00:34:35,090 --> 00:34:40,930
ู„ู„ุชุฐูƒูŠุฑ ุงู„ู€ phagocytic function ูŠุนู†ูŠ ุฅุฐุง ูƒุงู† ููŠู‡ ุฎู„ู„ ููŠ
394
00:34:40,930 --> 00:34:48,910
ุฎุทูˆุงุช ุงู„ู€ phagocytosis ูู‚ุท ู„ู„ุชุฐูƒูŠุฑ phagocytosis ุฎุทูˆุงุช
395
00:34:48,910 --> 00:34:54,620
ุงู„ู€ phagocytosis ู‡ูŠ ุงู„ู€ Adhesion ุซู… ุงู„ู€ Diapedesis ุซู… ุงู„ู€
396
00:34:54,620 --> 00:35:00,340
chemotaxis ุซู… ุงู„ู€ Phagocytosis ุซู… ุงู„ู€ Killing ูˆ
397
00:35:00,340 --> 00:35:07,080
ุงู„ุชุงู„ูŠ ููŠ ุบูŠุงุจ ููŠ ูƒู„ ู…ุฑุญู„ุฉ ู…ู† ุงู„ู…ุฑุงุญู„ ู‡ุฐู‡ ูŠุคุฏูŠ ู„ู‡ุง
398
00:35:07,080 --> 00:35:11,280
ูƒู„ ู…ุฑุญู„ุฉ is combined or is associated with certain
399
00:35:11,280 --> 00:35:18,460
disease ู…ุงุดูŠ ุฅุฐุง ุตุงุฑ ููŠู‡ ุจุฑุถู‡ ุฎู„ู„ ู…ุถุฑูŠ ู…ุนู†ุงุชู‡ ูƒู„
400
00:35:18,460 --> 00:35:22,550
ุงู„ู…ุฑุงุญู„ ุงู„ู„ูŠ ู‚ุฏ ุชู„ูŠู‡ุง ูˆุงู‚ูุฉ ูˆุฅุฐุง ูƒุงู† ุงู„ุฎู„ู„ ุญุฏุซ
401
00:35:22,550 --> 00:35:27,990
ู…ุซู„ู‹ุง ู…ุซู„ู‹ุง ููŠ ุงู„ู€ LAD ู…ุซู„ู‹ุง ู…ุซู„ู‹ุง ู…ุซู„ู‹ุง ู…ุซู„ู‹ุง ู…ุซู„ู‹ุง
402
00:35:27,990 --> 00:35:29,070
ู…ุซู„ู‹ุง ู…ุซู„ู‹ุง ู…ุซู„ู‹ุง ู…ุซู„ู‹ุง ู…ุซู„ู‹ุง ู…ุซู„ู‹ุง ู…ุซู„ู‹ุง ู…ุซู„ู‹ุง
403
00:35:29,070 --> 00:35:32,470
ู…ุซู„ู‹ุง ู…ุซู„ู‹ุง ู…ุซู„ู‹ุง ู…ุซู„ู‹ุง ู…ุซู„ู‹ุง ู…ุซู„ู‹ุง ู…ุซู„ู‹ุง ู…ุซู„ู‹ุง ู…ุซู„ู‹ุง ู…ุซู„ู‹ุง
404
00:35:32,470 --> 00:35:33,030
ู…ุซู„ู‹ุง ู…ุซู„ู‹ุง ู…ุซู„ู‹ุง ู…ุซู„ู‹ุง ู…ุซู„ู‹ุง ู…ุซู„ู‹ุง ู…ุซู„ู‹ุง ู…ุซู„ู‹ุง ู…ุซู„ู‹ุง ู…ุซู„ู‹ุง
405
00:35:33,030 --> 00:35:37,450
ู…ุซู„ู‹ุง ู…ุซู„ู‹ุง ู…ุซู„ู‹ุง ู…ุซู„ู‹ุง ู…ุซู„ู‹ุง ู…ุซู„ู‹ุง ู…ุซู„ู‹ุง ู…ุซู„ู‹ุง ู…ุซู„ู‹ุง ู…ุซู„ู‹ุง
406
00:35:37,450 --> 00:35:43,450
ู…ุซู„ู‹ุง ู…ุซู„ู‹ุง ู…ุซู„ู‹ุง ู…ุซู„ู‹ุง
407
00:35:44,920 --> 00:35:49,480
LAD ู‡ูˆ ุจุฑู†ุงู…ุฌ group of disorders ุจูŠุชู…ูŠุฒ ุจุฃู†ู‡ ุจูŠุตูŠุฑ
408
00:35:49,480 --> 00:35:52,560
ููŠู‡ ุฎู„ู„ ููŠ ุงู„ู€ interaction ู…ุง ุจูŠู† ุงู„ู€ leukocyte ู…ุน
409
00:35:52,560 --> 00:36:00,660
ุงู„ู€ vascular endothelial cells ูˆุทุจุนุง ู‡ุงูŠ ุงู„ู…ุฑุงุญู„
410
00:36:00,660 --> 00:36:04,700
ุทุจุนุง ุฌุงู„ูˆุง ููŠู‡ ุฃูƒุซุฑ ู…ู† ู…ุฑุญู„ุฉ ู„ู„ู€ LAD disease ูˆ
411
00:36:04,700 --> 00:36:09,240
ู‚ุณู…ูˆู‡ุง ู„ุซู„ุงุซ ู…ุฑุงุญู„ LAD 1, LAD 2, LAD 3 ูˆุฒูŠ ู…ุง
412
00:36:09,240 --> 00:36:13,400
ุงู†ุชูˆุง ุดุงูŠููŠู† ููŠ LAD 1 ุจูŠุตูŠุฑ ููŠู‡ ุฎู„ู„ ููŠ ุงู„ู€ diapedesis
413
00:36:15,830 --> 00:36:20,730
ููŠ ุงู„ู€ LAD 2 ุจูŠุตูŠุฑ ููŠู‡ ุฎู„ู„ ููŠ ุงู„ู€ adhesion ููŠ ุงู„ู€ LAD
414
00:36:20,730 --> 00:36:23,330
3 ุจูŠุตูŠุฑ ููŠู‡ ุฎู„ู„ ููŠ ุงู„ู€ activation ุงู„ู„ูŠ ู‡ูŠ
415
00:36:23,330 --> 00:36:27,450
ุงู„ู€ Phagocytosis ุจูŠุตูŠุฑ ููŠู‡ุง ุฎู„ู„ ู…ุงุดูŠ ุงู„ูŠูˆู… ุจูŠุตูŠุฑ ููŠู‡
416
00:36:27,450 --> 00:36:33,290
ุฎู„ู„ ููŠ ูˆุงุญุฏ ุงู„ู„ูŠ ู‡ูŠ ุงู„ู€ adhesion ุฃูˆู„ ูˆุงุญุฏุฉ ุจูŠุตูŠุฑ
417
00:36:33,290 --> 00:36:38,130
ููŠู‡ ุฎู„ู„ ููŠ ูƒู„ ู‡ุฐู‡ ุงู„ู…ุฑุงุญู„ ู…ุงุดูŠ ูุงู„ูŠูˆู… ุจูŠุตูŠุฑ ููŠู‡
418
00:36:38,130 --> 00:36:41,270
ุฎู„ู„ ููŠ ุฃุฎุฑ ูˆุงุญุฏุฉ ุงู„ู„ูŠ ู‡ูŠ ุงู„ู€ activation ุทุจุนุง ุจูŠุญุตู„
419
00:36:41,270 --> 00:36:51,110
ููŠู‡ ุฃู…ุฑุงุถ ุฒูŠ ุงู„ู€ Chediak Higashi Syndrome ูˆ ุงู„ู€ CDD ู‡ุงูŠ
420
00:36:51,110 --> 00:36:53,510
ุงู„ู„ูŠ ู‡ุงุฏ ูˆุงุญุฏ ุญุถุฑ ุนู† ุงู„ู€ autosomal recessive
421
00:36:53,510 --> 00:36:58,870
disease ู…ุฑุชุจุทุฉ ุจุงู„ูƒุฑูˆู…ูˆุฒูˆู… ุฑู‚ู… 22 ุงู„ู…ุฑุถู‰ ุนู†ุฏู‡ู… ุงู„ู€
422
00:36:58,870 --> 00:37:03,690
effect ุฅู† ู‡ุชูƒูˆู† subunits of integrin molecule ูˆู‡ุฐุง
423
00:37:03,690 --> 00:37:09,210
ุจูŠุคุฏูŠ ุฅู„ู‰ ุงู„ู„ูŠ ู‡ูˆ ุฅู†ู‡ adhesion to feel adhesion
424
00:37:09,210 --> 00:37:12,740
and migration of all white blood cells in the body
425
00:37:14,860 --> 00:37:18,980
ููŠ ุงู„ุฃุฏูˆูŠุฉ ุงู„ู…ุฑุถู‰ ุจูŠุญุตู„ ุนู†ุฏู‡ู… recurrent soft tissue
426
00:37:18,980 --> 00:37:22,760
bacterial infection ูˆูŠุฒูŠุฏ ุงู„ูˆู‚ุช blood cell count
427
00:37:22,760 --> 00:37:27,540
ู„ูƒู† ุจุฏูˆู† pus formation ูŠุนู†ูŠ ู…ุงููŠุด activity ูˆู…ุงููŠุด
428
00:37:27,540 --> 00:37:31,060
ูƒู„ ุงู„ุฃุฎู…ุงุช ุงู„ู„ูŠ ูˆุฑุง ุงู„ู€ adhesion ุฃูˆ ุงู„ู€ effecting
429
00:37:31,060 --> 00:37:35,140
wound healing lymphocyte function is also affected
430
00:37:35,140 --> 00:37:39,500
due to the lack of lymphocyte functioning antigen
431
00:37:39,500 --> 00:37:44,860
presentation ุงู„ู€ LAD 2 ู‚ู„ู†ุง ุจูŠุตูŠุฑ ููŠู‡ defect in
432
00:37:44,860 --> 00:37:50,180
selecting ุงู„ู€ ligand ูˆุงู„ู€ underlying defect ุงู„ู„ูŠ
433
00:37:50,180 --> 00:37:54,400
ู‡ูˆ LAD 2 ุจูŠุตูŠุฑ
434
00:37:54,400 --> 00:37:58,700
ููŠู‡ ุฃูŠุถู‹ุง ุฎู„ู„ ููŠ ุงู„ู€ leukocyte function ูˆ ุฏู‡ ุจูŠุคุฏูŠ
435
00:37:58,700 --> 00:38:03,140
ุฅู„ู‰ ุบูŠุงุจ ุงู„ู€ leukocyte ligand for selecting to be
436
00:38:03,140 --> 00:38:08,560
bind ูˆุฏู‡ ู…ุซู„ ุฃูˆ ุตูˆุฑุฉ ุญู„ูˆุฉ ู„ู‡ุฐุง ุงู„ู…ูˆุถูˆุน ุงู„ู€ LAD ูˆุงุญุฏ
437
00:38:08,560 --> 00:38:18,290
ููŠ ุงู„ุดูŠุก ู‡ูŠ ุนุจุงุฑุฉ ุนู† antigen ู…ุงุดูŠ LAD ุงุชู†ูŠู† ุนุจุงุฑุฉ ุนู†
438
00:38:18,290 --> 00:38:24,270
rolling Selected ุชูƒูˆู† ุบูŠุฑ ุฑู‚ู… ุชู„ุงุชุฉ ุงู„ู„ูŠ ู‡ูˆ ุงู„ู€
439
00:38:24,270 --> 00:38:31,110
activation is defected ุทุจุนุง ู‡ุฐุง ูƒู„ู‡ ููŠ LAD ูˆุงุญุฏ ุจุณ
440
00:38:31,110 --> 00:38:36,070
ููŠู‡ ุฎู„ู„ ููŠ ุงู„ุงุฑุชุจุงุท ูˆุงู„ู€ transmigration ุงู„ู„ูŠ ู‡ูˆ
441
00:38:45,690 --> 00:38:52,590
ุงู„ู€ integrins ุงูˆ ุงู„ู€ organelles ุจูŠุตูŠุฑ
442
00:38:52,590 --> 00:38:57,750
ููŠ ุนู†ุฏู‡ุง ู‚ู„ุฉ ููŠ ุงู„ู€ interest of the organism ูˆ this
443
00:38:57,750 --> 00:39:00,470
results in
444
00:39:02,700 --> 00:39:11,060
phagosome formation
445
00:39:11,060 --> 00:39:11,740
phagosome formation
446
00:39:11,740 --> 00:39:17,280
phagosome formation
447
00:39:17,280 --> 00:39:22,200
phagosome formation
448
00:39:23,380 --> 00:39:26,020
ู…ุฎู„ูˆู‚ ูƒุจูŠุฑ ู…ู† ุงู„ู…ุฎู„ูˆู‚
449
00:39:26,020 --> 00:39:27,180
ุงู„ู…ุฎู„ูˆู‚
450
00:39:27,180 --> 00:39:30,020
ุงู„ู…ุฎู„ูˆู‚
451
00:39:30,020 --> 00:39:31,620
ุงู„ู…ุฎู„ูˆู‚
452
00:39:31,620 --> 00:39:33,240
ุงู„ู…ุฎู„ูˆู‚
453
00:39:33,240 --> 00:39:38,680
ุงู„ู…ุฎู„ูˆู‚
454
00:39:38,680 --> 00:39:40,940
ุงู„ู…ุฎู„ูˆู‚
455
00:39:40,940 --> 00:39:46,160
ุงู„ู…ุฎู„ูˆู‚
456
00:39:48,980 --> 00:39:53,040
ูˆุจุงู„ุชุงู„ูŠ ุจูŠุญุตู„ ููŠู‡ ุนู…ู„ูŠุฉ Phagocytosis ู„ูƒู† ู…ุงููŠู‡
457
00:39:53,040 --> 00:39:57,600
killing ูˆุจูŠุญุตู„ ููŠู‡ intracellular survival
458
00:39:57,600 --> 00:40:03,060
ูุงู„organism ุจูŠุคุฏูŠ ุฅู„ู‰ granuloma formation Mutation
459
00:40:03,060 --> 00:40:06,380
ูˆุฌุฏูˆู‡ุง ููŠ ุงู„ู€ enzymes which catalyzes the
460
00:40:06,380 --> 00:40:10,800
respiratory burst ูˆุจูŠุญุตู„
461
00:40:10,800 --> 00:40:17,120
ููŠู‡ ู‚ู„ุฉ ููŠ ุงู„ู€ intracellular killing ู…ุญุตู„ุฉ ุฃูˆ ุบูŠุงุจ
462
00:40:19,320 --> 00:40:22,700
ูˆุจู†ู„ุงุญุธ ู‡ุฐู‡ ุงู„ุญุงู„ุงุช ููŠ ุฃูˆู„ ุดู‡ุฑ ุฃูˆ ุฃูˆู„ ุณู†ุชูŠู† ู…ู†
463
00:40:22,700 --> 00:40:31,400
ุงู„ุนู…ุฑ ุจูŠุตูŠุฑ ุนู†ุฏู‡ recurrent infection ุญุชู‰ ุฃุถุนู ุงู„ู€
464
00:40:31,400 --> 00:40:35,660
microbes ู…ุฑุฉ
465
00:40:35,660 --> 00:40:40,720
ุขุฎุฑ interferon gamma receptor deficiency ุจูŠุตูŠุฑ ููŠู‡
466
00:40:40,720 --> 00:40:43,900
mutation ููŠ ุงู„ู€ interferon ุนุงุฆู„ุฉ ุฃุฎุฑู‰ ู…ู† ุนุงุฆู„ุงุช ุงู„ู€
467
00:40:43,900 --> 00:40:48,030
receptor ุจูŠุคุฏูŠ ุฅู„ู‰ inability of a monocyte to
468
00:40:48,030 --> 00:40:53,450
respond to Gamma Interferon ูˆุจุงู„ุชุงู„ูŠ
469
00:40:53,450 --> 00:40:56,430
ููŠ ุงู„ู€ secretion of the tumor necrosis factor Alpha
470
00:40:56,430 --> 00:41:01,850
ุงู„ู€ patients are susceptible to weakly pathogenic
471
00:41:01,850 --> 00:41:03,290
mycobacteria
472
00:41:06,330 --> 00:41:10,090
ู‡ูˆ ุงู„ู€ Natural Killer Cell Deficiency ุงู„ู„ูŠ ู†ุนุฑูู‡
473
00:41:10,090 --> 00:41:15,130
ุจูŠุฃุซุฑ ุนู„ู‰ ุงู„ู€ NK cell ุจูŠุคุฏูŠ ุฅู„ู‰ ุงู„ู€ Impaired
474
00:41:15,130 --> 00:41:19,090
Allograft Rejection ู…ุงููŠุด ุดูŠุก ุงู„ู€ Impairment
475
00:41:19,090 --> 00:41:24,930
Rejection And is linked to higher susceptibility
476
00:41:24,930 --> 00:41:29,170
to viral disease ูˆุจูŠุตูŠุฑ ููŠู‡ metastasis from tumor
477
00:41:31,140 --> 00:41:36,500
ุงู„ู€ NK cells seen in Skid some T and phagocytic
478
00:41:36,500 --> 00:41:40,540
cell disorder and in X-linked lymphoproliferative
479
00:41:40,540 --> 00:41:47,360
syndrome ุงู„ุงูˆุฑุงู‚
480
00:41:47,360 --> 00:41:56,880
ุงู„ู„ูŠ ุจุชุชุนู„ู‚ ุจุงู„ู€ complement ูŠุนู†ูŠ ุงู„ู€ ..ุงู„ู€
481
00:41:56,880 --> 00:42:00,180
complement component ุงู„ุงูˆู„ุงู†ูŠุฉ ู…ู‡ู…ุฉ ุฌุฏุง for
482
00:42:00,180 --> 00:42:07,300
opsonization ุฒูŠ C3P ุบุงู„ุจุง deficiency of complement is
483
00:42:07,300 --> 00:42:14,700
associated with SLE disease ูˆู‡ูŠ ุงู„ู€ complement
484
00:42:14,700 --> 00:42:22,740
ุจุชุดุชุบู„ ุจู…ูŠูƒุงู†ุฒู… classical ูˆ alternative ุทุจุนุง
485
00:42:22,740 --> 00:42:32,270
ุฒูŠ ู…ุง ุงู†ุชูˆุง ุดุงูŠููŠู† ุงู„ู„ูŠ ู‡ูˆ ุณูˆุงุก ูƒุงู† alternative ุงูˆ
486
00:42:32,270 --> 00:42:38,110
lectin pathway ุงูˆ even classical ุบูŠุงุจู‡ุง ุจูŠุฏูŠ ู„ู€ diseases
487
00:42:38,110 --> 00:42:42,330
ู…ุฎุชู„ูุฉ ูููŠ ุงู„ุจุฏุงูŠุฉ infections with
488
00:42:42,330 --> 00:42:46,630
encapsulated microorganism ุจู‚ุฏู… ุดูˆูŠุฉ rheumatoid
489
00:42:46,630 --> 00:42:51,190
disease ูˆุงุณุฆู„ุฉ ุงูŠู‡ ุชุญุช ุงุฐุง ูƒุงู† ููŠ ุงู„ู…ุงูƒ ุงูˆ ุงู„ู€
490
00:42:51,190 --> 00:42:56,830
membrane attack complex ุจูŠุตูŠุฑ ููŠู‡ Neisseria gonorrhoeae ุงูˆ
491
00:42:56,830 --> 00:43:03,260
Neisseria meningitidis ุฃูŠ ู…ุฑูŠุถ ุจู€ Deficiency of C1,4,2 ุงู„ู„ูŠ
492
00:43:03,260 --> 00:43:07,160
ู‡ูˆ ุงู„ุจุฏุงูŠุงุช ู…ู† ุงู„ู€ Classical Pathway ุงูˆ C3
493
00:43:07,160 --> 00:43:11,100
Deficiency ู†ูุณู‡ุง ุจูŠุตูŠุฑ ููŠู‡ ุฒูŠุงุฏุฉ ููŠ ุงู„ู€ Infection
494
00:43:11,100 --> 00:43:14,180
ุฃูˆ ุงู„ู€ Encapsulated Microorganism ุญุณุจ ุงู„ุฌุฏูˆู„ ุงู„ู„ูŠ
495
00:43:14,180 --> 00:43:18,080
ุดูู†ุงู‡ ุทูˆูŠ ุฒูŠ Streptococcus pneumoniae ูˆ ุงู„ู€ Haemophilus
496
00:43:18,080 --> 00:43:24,720
ูˆ ุงู„ุงู†ูู„ูˆู†ุฒุง ูˆ ุฃุฒู…ุฉ ุฑูˆู…ุงุชูŠุฒู…ูŠุฉ ุจุณุจุจ ุชู†ุธูŠู ุบูŠุฑ ุตุญูŠุญ
497
00:43:24,720 --> 00:43:25,480
ู„ู„ู…ุนุงู…ู„ุงุช ุงู„ู…ู†ุงุนูŠุฉ
498
00:43:29,040 --> 00:43:33,640
ุงู„ู€ Deficiency of the mannose binding lectin
499
00:43:33,640 --> 00:43:38,100
ุจูŠุคุฏูŠ ุงู„ู‰ ุทุจุนุง ุงู„ู…ูˆุฌูˆุฏ ุนู„ู‰ ุงู„ู€ surface of microbe
500
00:43:38,100 --> 00:43:45,040
with or without antibody and activate the
501
00:43:45,040 --> 00:43:50,240
classical pathwayุฃูŠุถู‹ุง ุจูŠุคุฏูŠ ุบูŠุงุจู‡ ุฅู„ู‰ risk of
502
00:43:50,240 --> 00:43:56,380
infection and SLE-like symptoms. ุบูŠุงุจ C3 associated
503
00:43:56,380 --> 00:44:04,700
with symptoms ุฎุตูˆุตู‹ุง ุงู„ู€ complications ุชุจุนุชู‡ุง ุบูŠุงุจ
504
00:44:04,700 --> 00:44:08,480
ุงู„ู€ lead complement component ููŠ ุงู„ุขุฎุฑ ูŠุนู†ูŠ ุงู„ู€ MAC
505
00:44:08,480 --> 00:44:14,160
ุฒูŠ C56789 ุงู„ู„ูŠ ุจูŠูƒูˆู†ูˆุง ุงู„ู€ MAC ุงู„ู„ูŠ ู‡ูˆ membrane
506
00:44:14,160 --> 00:44:21,270
attack complex. It's directly related to the primary
507
00:44:21,270 --> 00:44:27,010
defect against gram-negative bacteria ุฎุตูˆุตู‹ุง
508
00:44:27,010 --> 00:44:30,450
ู†ูŠุณูŠุฑูŠุง. Defective
509
00:44:30,450 --> 00:44:34,010
control of the complement component. ูŠุนู†ูŠ ุญุชู‰ ุงู„ู€
510
00:44:34,010 --> 00:44:37,930
control ุฅุฐุง ุตุงุฑ ููŠู‡ deficiency ุฒูŠ ุงู„ู€ hereditary
511
00:44:37,930 --> 00:44:43,850
angioedema. ู…ุดู‡ูˆุฑุฉ ูƒุชูŠุฑ ุบูŠุงุจ C1 esterase inhibitor
512
00:44:45,150 --> 00:44:51,370
ุจูŠุฏู‰ ุงู„ู‰ ุงู„ู„ู‰ ู‡ูˆ ุงู„ู€ hereditary angioedema ุทุจุนุง
513
00:44:51,370 --> 00:44:54,590
ูƒู…ูŠุฉ ูƒุจูŠุฑุฉ ู…ู† ุงู„ู€ vasoactive peptide. patient
514
00:44:54,590 --> 00:44:59,370
suffering from localized edema. ูˆ it's life
515
00:44:59,370 --> 00:45:03,850
threatening when it occurs in the larynx. ุงู‡ ุทุจุนุง
516
00:45:03,850 --> 00:45:07,230
ุจูŠุตูŠุฑ ููŠู‡ ุงุด edema ููŠ ุงู„ู€ larynx ูˆ ุงู„ุชุงู†ู‰ ุจูŠุตูŠุฑ ููŠู‡
517
00:45:07,230 --> 00:45:12,730
obstruction ู„ู„ู€ airway pathway. treatment
518
00:45:12,730 --> 00:45:19,410
ุบุงู„ุจุง avoid trauma and infusion of C1 esterase
519
00:45:19,410 --> 00:45:25,350
inhibitor. ุงู„ุฌู„ูŠูƒูˆุฒูŠู† ุงู„ูุณูุฉ ุฏูŠ ุงู„ู€ enacetol protein
520
00:45:25,350 --> 00:45:33,270
deficiency. ู†ุนุฑู ุงู† ู‡ุฐุง ุจู„ุนุจ ุฏูˆุฑ ูƒุจูŠุฑ ููŠ ุงู„ู€ as
521
00:45:33,270 --> 00:45:35,670
anchored protein.
522
00:45:37,690 --> 00:45:44,190
ู‡ุฐุง ุนุจุงุฑุฉ ุนู† ุนุงุฆู„ุฉ ู…ู† ุงู„ุจุฑูˆุชูŠู†ุงุช ูˆุงู„ุฌู„ูŠูƒูˆุฒูŠู‡
523
00:45:44,190 --> 00:45:48,530
ุงู„ููˆุณูุงุช ุฏูŠุงู„ ุงู„ู†ุงุณูŠุชูˆู‡ ุงู„ุงู†ูƒูˆู„ุงุช is expressed ุนู„ู‰
524
00:45:48,530 --> 00:45:51,110
ุงู„ู€ membrane of RBCs, lymphocyte, granulocyte
525
00:45:51,110 --> 00:45:54,590
endothelial cell and epithelial cell. ู…ุนุธู… ุงู„ุฎู„ุงูŠุง
526
00:45:55,790 --> 00:45:58,450
ุทุจุนุง DC protein ู‡ู… ุนุจุงุฑุฉ ุนู† ุงู„ุจุฑูˆุชูŠู†ุงุช ุญู…ุงูŠุฉ
527
00:45:58,450 --> 00:46:02,930
ู„ู„ุฎู„ุงูŠุง ู…ู† ุงู„ู€ complement activity ูˆุจุงู„ุชุงู„ูŠ ุบูŠุงุจู‡ู…
528
00:46:02,930 --> 00:46:12,770
ูŠุคุฏูŠ ุฅู„ู‰ ุบูŠุงุจ ุงู„ู€ destruction of cell. ุทุจุนุง
529
00:46:12,770 --> 00:46:20,730
ูƒู„ ุงู„ุฎู„ุงูŠุง ุชุชุฃุซุฑ ููŠ ู‡ุฐุง ุงู„ู…ูˆุถูˆุน ูˆุจุงู„ุชุงู„ูŠ the ุฃูŠุถุง
530
00:46:22,580 --> 00:46:26,300
ุจูŠุตูŠุฑ ููŠู‡ hemolysis for all these cells. ุทุจุนุง ุฃุดู‡ุฑ
531
00:46:26,300 --> 00:46:29,800
ู‡ุฐู‡ ู„ู„ุบุงูŠุฉ ุงู„ู„ูŠ ู‡ูˆ ุงู„ู€ PNH. ููŠ ุงู„ู€ PNH ุทุจุนุง ุงู„ู€
532
00:46:29,800 --> 00:46:33,760
patient ุจูŠุตูŠุฑ ููŠู‡ ุบูŠุงุจ ู„ู„ู€ enzyme required for
533
00:46:33,760 --> 00:46:39,840
production of GBI ุงู„ู„ูŠ ู‡ูˆ ูˆุจุงู„ุชุงู„ูŠ ู…ุงููŠุด GBI ุนู†ูƒู…
534
00:46:39,840 --> 00:46:43,680
ุงู„ู€ protein ูˆุจุงู„ุชุงู„ูŠ ู…ุงููŠุด ุจุฑูˆุชูŠู†ุงุช ุญู…ุงูŠุฉ ุนุดุงู† ู‡ูŠูƒ
535
00:46:43,680 --> 00:46:50,200
ุจุฒูŠุฏ ุงู„ู€ susceptibility to hemolysis ููŠ ุงู„ู€ Chronic
536
00:46:50,200 --> 00:46:53,580
course of P.N.H. Intravascular Hemolysis or CARE
537
00:46:53,580 --> 00:46:59,060
ุทุจุนุง ููŠ ุงู„ูƒุฏู†ู‰ ูˆู‡ุฐุง ุจูŠู‚ุฏู‰ ุงู„ู‰ ุงู„ู„ู‰ ู‡ูˆุง activation
538
00:46:59,060 --> 00:47:03,700
of complement. ูŠุนู†ู‰ ูู‰ degeneration ู„ู„ุชุดูˆ ุฃูˆ damage
539
00:47:03,700 --> 00:47:08,740
ู„ู„ุชุดูˆ ูˆู†ุชูˆู‚ู
540
00:47:08,740 --> 00:47:12,520
ู‡ู†ุง ู„ู†ุณุชูƒู…ู„
541
00:47:12,520 --> 00:47:14,220
ูู‰ ู…ุฑุญู„ุฉ ู‚ุงุฏู…ุฉ ุงู† ุดุงุก ุงู„ู„ู‡